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This thesis highlights two studies which seek to link phenotypic presentations in cystic 
fibrosis (CF) and CF-like disease with underlying causative variation.  Cystic fibrosis is a rare 
Mendelian disorder with a primary phenotype of highly viscous secretions in the lung, pancreas, 
and intestines.  The current life expectancy for CF patient is ~50 years or age, and the primary 
cause of mortality is progressive lung disease.  Individuals with this disorder carry two disease 
causing alleles in the cystic fibrosis transmembrane conductance regulatory gene (CFTR). 
However, there are individuals which present with a similar but mild CF-like disease who 
completely lack causative mutations at the CFTR locus.  In Chapter 2, I report the discovery and 
functional analysis of mutations within a candidate causative locus, CA12, in these ‘atypical’ CF 
patients. Our study details three novel variants in CA12 or carbonic anhydrase XII which are 
inherited in a recessive fashion in two unrelated pedigrees. We show that these variants, as well 
as previously reported variants, are complete loss of function through extensive localization and 
functional studies.  Given CA12’s role in bicarbonate buffering, this study sheds new light on the 
importance of bicarbonate in CF disease. 
There are over 2000 known variants within CFTR. However, the most common causative 
allele is deletion of phenylalanine at amino acid position 508, often referred to as F508del.  
Nearly 50% of all CF patients are homozygous for this allele, yet these patients exhibit a range of 
disease severity or phenotypic heterogeneity.  In Chapter 3 of this work, I present a study which 
sought to discover rare and previously untyped common variation within and surrounding CFTR 
that could modify disease severity in the F508del homozygous CF population.  My findings 
suggest that a burden of variants which associate with CF traits exists at key loci throughout the 
CFTR genomic region.  These loci include previously identified CTCF binding sites and other 
regulatory regions of interest.  This study demonstrates the utility of re-seqeuncing a disease 
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The Cystic Fibrosis Phenotype 
Cystic fibrosis, or CF, is a disease affecting ~70,000 individuals worldwide, and 
nearly 30,000 individuals in the US (1).  CF is a rare recessive Mendelian disorder, with a 
carrier frequency ranging from 1/30 to 1/17 in Caucasians of European descent, the 
primary affected population (2).  Individuals with CF develop unusually viscous or 
otherwise altered secretions in several tissues including the lungs, pancreas, sweat duct, 
liver, intestines, and male reproductive tracts.  These manifestations are further detailed 
in the following literature review, a natural history of CF. 
In 1606, a Professor of Medicine at Henares in Spain noted that one’s fingers 
would taste salty after rubbing the forehead of a ‘bewitched’ child (3).  This is one of 
many similar early accounts of the later understood medical condition cystic fibrosis. 
This was a keen observation as the chloride concentration in sweat is one of the primary 
assays currently used to diagnose patients with CF.  Healthy individuals typically have 
sweat chloride level measurements less than 40mM, whereas individuals with classic CF 
have measurements exceeding 60mM (4).   Still, some individuals have intermediate 
values (40-60mM), and further testing is needed for diagnosis (see below: Atypical 
Cystic Fibrosis and Chapter 2) (5).  While salty sweat was perhaps the first trait 
observed in CF, it was not fully appreciated until centuries later – likely because the 
primary cause of morbidity in these patients involved other tissues. 
Pancreatic and intestinal manifestations of this disease had been reported as early 
as 1888, and were often mistaken as unusual cases of celiac disease (6). The term cystic 




introduced as “fibrocystic disease of the pancreas” (7).  She observed patients with CF 
that had unusually thick secretions in the pancreas.  These viscous secretions lead to 
pancreatic insufficiency in 85% of CF patients (8).  The inability to digest and absorb 
nutrients was the primary cause of mortality in CF until the introduction of pancreatic 
enzymes in the late 1970s (9).  A decrease in pancreatic function is evident at birth in 
many CF patients, and serum immunoreactive trypsinogen (a pancreatic enzyme 
precursor) levels are used today as a pre-natal screen for the disease (10).  
Additional mortality in some CF patients was due to meconium ileus (MI).  This 
is an intestinal blockage most common in CF patients, but present in the general 
population.  It was originally described by Karl Freiherr von Rokitansky in 1838 
following the autopsy of an infant with “yellow jelly-like meconium…sticking to the 
outside of the bowel” (3).  Mortality of CF patients with MI was nearly 70% by age one 
in 1940 (11).  Advances in detection and surgical correction of this blockage have greatly 
reduced mortality in patients with MI to that of the general CF population. 
 Once CF patients were living beyond early childhood (primarily due to 
pancreatic enzymes correcting malabsorption), an additional trait became the major cause 
of mortality: lung disease.  Perhaps the first account of a CF patient with lung disease 
occurred in 1934 by a Dutch physician, GJ Huet (3).  In addition to pancreatic 
insufficiency, the patient he reported had chronic cough beginning at age six, and died of 
bronchopneumonia at age 10.  Lung disease was later described more formally in 1938 in 
Dr. Dorothy Anderson’s review of her own patients and literature case reports, “For 
weeks or months it remained as a chronic cough, gradually increasing in severity, with 




any combination of these conditions” (12). Lung disease due to recurrent infections 
followed by inflammation leads to eventual pulmonary failure and mortality in CF 
patients today.  
In 1944, a great breakthrough in the treatment of lung infections was made 
available to CF patients, Penicillin (13). When this and other antibiotics were introduced 
to the treatment regimen of CF patients, clinical course improved significantly (14).  This 
and other modern treatments such as physical therapy, inhaled steroids, and  mucolytics 
have increased the average life expectancy for patients with CF to nearly 50 years of age 
(for children born today and projecting the same rate of progress in therapeutics) (15).  
Molecular Etiology of Cystic Fibrosis 
 While the clinical course of CF was well appreciated in the early 20th century, 
understanding the underlying defect leading to symptoms would take much longer.  The 
unusual pathology of the lung epithelium in CF patients was first described in 1923 as “A 
striking finding in the lungs was the epithelial lining of the bronchioles, which in many 
instances was definitely of a stratified squamous type and showed desquamation of the 
horny superficial portions”.  The same manuscript details unusual epithelial surfaces in 
other CF related tissues like the pancreas (16).  These findings were eventually thought to 
be caused by the thick mucus and secretions in the same tissues.  In the 1930s, a 
connection was established between abnormal lung epithelia and frequent infections (17).  
The observation linking lung disease to unusual epithelial morphology was first made for 




nearly a decade before additional insight into the molecular etiology of this disease was 
gained. 
 In 1951, Dorothy Anderson and Walter Kessler noticed an unusually high 
frequency of cystic fibrosis patients being admitted for dehydration during a heat wave 
(18).  At this time, they speculated that perhaps it was a deficiency of the sweat gland in 
these patients, who (as noted above) had very salty sweat.  The abnormally high sweat 
chloride concentrations in these patients were first quantified in 1953(19).  Sweat testing 
as a diagnostic tool was later standardized by Gibson and Cooke (20).  This was the first 
insight into a possible cause of the disorder; however, it was unappreciated for nearly 
another two decades as scientists pursued other hypotheses (21).  These included the 
possibility of diffusible “factors” which may somehow alter CF patient lung secretions. 
 Significant enhancements were made in understanding the basic defect of CF in 
the 1980s.  The first report of a possible defect in epithelial ion transport was on a poster 
presented at the 8
th
 international congress on CF (22), “the existence of an extraordinarily 
active sodium absorption could explain some of the clinical findings of CF e.g. 
hyperviscous mucus as being caused by excessive absorption of NaCl and water”.  One 
of the pivotal papers which significantly increased our understanding of CF pathology 
was that of Dr. Michael Knowles and his team at the University of North Carolina.  In 
1981, he reported that the potential difference across nasal epithelia in CF patients was 
aberrant (23).  Specifically, he was able to show that transport of both chloride and 
sodium was altered through use of specific inhibitors, and went on to hypothesize that 
this could be the primary defect in CF patients.   Because these findings were observed in 




disease, and suggested a strong genetic component.  Just a few years later, Paul Quinton 
(a renown CF researcher and CF patient) published another landmark paper detailing 
specifically a block of ion transport in the sweat duct (24).  Later, Dr. Ray Frizzell 
confirmed the presence of a chloride channel which was defective in CF epithelial cells 
(25).  We now know that defects in this channel, the cystic fibrosis transmembrane 
conductance regulator (CFTR), are the cause of CF. 
 In recent years, our understanding of the molecular etiology of CF has been 
further refined.  CFTR is a large ATP-gated anion channel which is found within the 
apical membrane of secretory epithelial cells in the lung, liver, pancreas, intestines, skin, 
and reproductive tract.  While its structure is similar to an ABC transporter, it functions 
as a channel with only passive transport.  It is capable of conducting chloride, 
bicarbonate, and thiocyanate down their concentration gradient (26).   
 In the lungs and pancreas, CFTR functions to regulate chloride flow from the 
hypertonic intracellular fluid into the hypotonic secretions above epithelial cells.  The 
movement of chloride occurs concurrently with the movement of sodium and water along 
their respective gradients, allowing for hydration of the epithelial surface.  In the lung, 
the height of the airway surface liquid (ASL) and composition of the mucus layer allows 
cilia at this surface to beat correctly, transporting mucus (and the constantly inhaled 
bacteria and allergens contained there-in) out of the lung and into the digestive tract.  
When CFTR is not present at the membrane, or not functional, chloride transport is 
disrupted.  This leads to dehydration of the mucus layer, inhibiting their ability of cilia to 
beat correctly and to clear particles trapped in mucous.  Because of this reduced 




ultimately leading to severe lung disease.  CFTR functions slightly differently in the 
sweat gland, where its primary role is resorption of chloride ions from the sweat(24).  In 
the sweat duct, defective CFTR results in a hypertonic solution as chloride is trapped 
outside of the epithelial layer.  This results in the salty sweat so characteristic of these 
patients, which continues to be used as a key diagnostic marker today.   
Discovery of the CFTR gene 
 Much of our understanding of the role of the CFTR protein stems from genetic 
studies of CF.  In 1985, family based genetic linkage studies were used to isolate the “CF 
gene” to the long arm of chromosome 7 (27-30).  In 1988, the gene had been further 
localized to 7q21-31, and haplotypes suggested there was one predominant mutation in 
Europeans (31).    
Finally, in 1989, several groups published the location and cloning of the cystic 
fibrosis gene, which they dubbed the cystic fibrosis transmembrane conductance 
regulator (32-34).  With the cloning and characterization of CFTR, significant insight was 
gained as to the structure and function of the protein.  It was also confirmed that the most 
common variant was a deletion of phenylalanine (3bp) within the first nucleotide binding 
domain (33).  This variant was present on a specific haplotype background in Europeans, 
and was primarily observed in pancreatic insufficient patients.  The remaining haplotypes 
of this gene were of low frequency, and subsets of them were more likely to occur in 
pancreatic sufficient patients (32).  This suggested there were many other disease-causing 





The Genotype  - Phenotype Correlation in CF 
We now know that over 2000 variants have been observed within CFTR, and 
some of these are known to be disease causing (35). The severity of disease in each 
patient is primarily determined by which CF-causing variants they have inherited (36).  
CF variants can be classified into several groups by their expected functional impact on 
the cystic fibrosis transmembrane conductance regulator, or CFTR (37).   
The most common mutation, F508del, is present (on either 1 chromosome or 
both) in nearly 70% of CF patients, where it results in the improper folding and eventual 
degradation of the final protein product (38).  Phenotypes of patients carrying this allele 
reflect the damage present at the molecular level.  Patients with two copies of F508del 
(~50% of the CF patient population) have an average sweat chloride of 102mM, 98% are 
pancreatic insufficient, and 60% develop a P. aeruginosa infection (39).  
Other disease causing variants result in less severe CF phenotypes.  For example, 
in patients carrying one copy of F508del and one copy of S1251N, a milder phenotype is 
observed.  Their average sweat chloride is 90 mM, only 78% are pancreatic insufficient, 
and 50% contract P. aeruginosa (39).   It is not shocking that these patients have a milder 
phenotype given the mutation, S1251N, results in a stable protein at the epithelial surface 
with partial chloride conductance.  Because S1251N CFTR has the primary defect of 
chloride conductance, it is often referred to as a “gating” mutation (40).   
However, the molecular defect in CFTR (be it inability to conduct chloride, lack 
of protein at the cell surface, or various other defects) does not always match with the 




(35).  In these scenarios, we may hypothesize that our initial assumption about the 
molecular defect resulting from a given mutation is invalid.  For example, a missense 
mutation near the end of an exon may result in mis-splicing of the forming mRNA 
transcript.  This could result in degradation of the erroneous transcript, no protein 
product, and thus a severe phenotype.  Given the large number of variants in the gene, we 
are just now beginning to investigate and understand the functional defect of many CFTR 
mutations.  This is an active area of research in our own and others’ laboratories. 
Phenotypic Heterogeneity in Cystic Fibrosis 
 There is extensive phenotypic heterogeneity even across CF patients carrying the 
same mutations in CFTR.  This phenomenon was initially noticed within pedigrees 
containing multiple affected individuals (41, 42).  In these families, some siblings would 
present with more or less severe lung disease or pancreatic function.  Given that siblings 
share many environmental factors, it is possible that the portion of genetic variation they 
do not share could alter their disease course.  This idea was systematically explored 
through hereditary studies of twins and siblings. 
 Initial twin and sibling based studies of lung disease heritability in cystic fibrosis 
were somewhat underpowered, and did not find a significant genetic contribution to the 
variability of this trait (43).  These studies speculated that shared factors such as genetics 
and environment likely did not contribute to lung disease severity (44).  
In a paper by Burkhard Tümmler in 2001, the chloride permeability of intestinal 
tissue as well as respiratory epithelia was studied in a cohort of F508del homozygous 




transport in their pulmonary tissues, and this correlated with milder disease.  Similar 
findings were observed in the intestinal tissues (45).  The authors speculated that these 
patients must have some functional CFTR present at the cell membrane.  Additionally, 
they noted that the chloride transport profiles observed were more concordant in 
monozygotic twins than in dizygotic twins and siblings.  Greater concordance indicated 
that genetic variation beyond the primary CFTR mutation (F508del in this case) was 
contributing to chloride secretion and disease severity.   
 In 2005, Garry Cutting and colleagues published a paper detailing 526 patients 
from the Johns Hopkins Twin and Sibling Study (TSS) (46).  In this manuscript, they 
found that cross sectional and 5 year longitudinal CF specific lung function percentiles 
were significantly more concordant for the monozygotic twin cohort.  These findings 
now strongly suggested a role for shared genetic factors, beyond the CFTR locus, 
contributing to lung disease severity. 
 The relative contributions of environmental, genetic, and stochastic factors have 
now been estimated for lung disease (47), as well as various other CF traits (37).  For 
example, variation in the risk of developing intestinal obstruction is nearly completely 
attributable to genetic factors (48).  Other traits such as P. aeruginosa rates have a larger 
environmental component (49).  Variation in sweat chloride levels has not been formally 
studied for relative contribution of genetic or environmental components.  However, 
work in the Cutting laboratory by J. Michael Collaco suggests that nearly 50% of the 
variability in this trait is derived from CFTR genotypes, with another 25% likely due to 
other genes, and a final 25% due to environmental or stochastic factors.  These studies 




Genetic Modifiers of Cystic Fibrosis Traits 
   Various loci were first suspected to modify CF traits.   These were primarily 
chosen based on a logical connection to the phenotype.   For example, the alpha1-
antitrypsin gene was known to have low functioning variant forms in European 
Caucasians.  Given that deficiency of this enzyme results in poor lung function in non-CF 
populations, it was a great candidate modifier of CF lung function. (50).  While this 
candidate was initially promising in small cohorts, later studies could not replicate an 
association between variants in alpha1-antitrypsin and lung disease severity (51).  For 
many years, choosing candidate loci based on a known function was the only method 
available to pursue modifier genes in CF (52-54).  In 2000, a consortium was formed in 
the CF genetics community in order to more systematically assay modifier loci. 
 Advances in high throughput methods of genotyping patients led to the 
development of genome wide association studies (GWAS) in the early 2000s (55).  These 
assays were developed to map genes which are associated with either common complex 
phenotypes (e.g. heart disease), or which modify Mendelian disease phenotypes.  And 
unlike previous genetic association studies to date, the sequencing of the human genome 
and use of single nucleotide polymorphism (SNP) genotyping arrays allowed for a 
genome-wide search. The CF research community took notice of this advancement, and 
the first GWAS for lung disease severity in CF patients was published in 2011 (56).  This 
paper by the international genetic modifier consortium detailed two key loci associated 
with lung disease severity: 11p13 and 20q13.2.  A subsequent GWAS in a larger CF 
cohort later replicated the 11p13 locus, and introduced 5 additional loci which may 




related diabetes and meconium ileus (58, 59).  However, this type of study has never been 
performed for sweat chloride levels – presumably because the degree of variance in this 
trait attributable to loci beyond CFTR is not well understood (see above reference to 
ongoing work by JM Collaco).  
The Search for Missing Heritability 
 A phenomenon that continues to perplex researchers today is the “missing 
heritability” present in GWAS (60).  Through twin and sibling studies, one can estimate 
the proportion of variance in a given trait due to shared inherited genetics; this is often 
termed ‘heritability’.  Similarly in GWAS, the total percentage of variance explained by 
each key finding can be calculated.  Missing heritability arises when the expected 
proportion of variance attributable to a trait through previous studies is significantly 
larger than the variance explained by GWAS.  This discrepancy may be due to a variety 
of factors including genetic epistasis (interactions of multiple genes) (61), linkage 
masking (62), dominant heritability models (63), and rare variation (64).  There is also 
missing heritability for lung disease severity in cystic fibrosis.  The most recent GWAS 
identified 5 loci, each with beta values less than 5% for the forced expiratory volume 
(FEV1) percent predicted measure of CF lung function(57).  The analyses in this 
manuscript indicate that there is still substantial missing heritability for this CF trait.  
 In an attempt to find additional genetic factors which may be contributing to lung 
disease severity in CF patients, Chapter 3 of this manuscript details a novel re-




previously untyped variants, within and surrounding the causative gene, could lead to 
phenotypic heterogeneity in a highly homologous population of CF patients.   
 Resequencing studies have been successful identifying rare variants of possible 
effect within GWAS loci.  A recent resequencing study for ulcerative colitis found many 
rare coding variants associated with the disease.  The authors speculated that these 
findings might provide insight into the structure and function of the genes involved, 
perhaps guiding development of therapeutics (65).  Unlike most re-sequencing studies, 
we opted to target the disease causing locus, rather than modifiers identified via CF 
GWAS. However, we and others are also pursuing these modifier loci in independent 
research projects.   
It may not be intuitive to sequence CFTR in patients whom have already had 
genotyping sufficient to determine their causative alleles (e.g. F508del, G551D, R117, 
etc).   Individuals in the U.S. are often screened at birth for cystic fibrosis through a blood 
spot test (IRT, see above) (10).  If a newborn screens positive, additional testing will be 
conducted, including genotyping of the CFTR locus.  This primary genotyping is usually 
conducted via a highly targeted array approach.  In cystic fibrosis, this panel may contain 
anywhere from 23 to over 100 known CF mutations (out of >2000 variants in the gene).  
Most individuals with CF will have mutations in one or two of these most frequently 
occurring mutations.  If two known disease causing mutations are detected, no further 
genotyping is usually required (66).  Therefore, much of the variation within and around 
this locus (introns, untranslated regions, and intergenic regions) goes completely untyped 
in these patients.  Newer diagnostic assays relying on “full” sequencing of the locus often 




In Chapter 3, I describe the extensive variation discovered in these 
uncharacterized regions in a large population of F508del patients, and how this variation 
may modulate disease traits. 
Atypical Cystic Fibrosis 
Sometimes, even after extensive genotyping of CFTR, patients with CF like 
phenotypes are found to carry no disease causing mutations at this locus.  These patients 
are said to have ‘atypical’ CF or CF-related disorders.  This distinct patient cohort was 
first recognized by Ron Rubenstein and Garry Cutting in 1998, “In approximately 2% of 
patients, there is an atypical phenotype, which consists of chronic sinopulmonary disease, 
pancreatic sufficiency, and either borderline (40 to 60 mmol/L) or normal (<40 mmol/L) 
sweat chloride concentrations”(68).  These findings were based on both personal 
observations and previous case reports of patients with mild CF phenotypes and one or no 
CFTR mutations (69-71).   
In his 2002 manuscript, Joshua Groman assessed CFTR mutations, function, and 
linkage in sibling sets and pedigrees with an atypical CF phenotype (72).  He found that 
patients entering the study with one known mutation in CFTR were more likely to have a 
second mutation upon further testing.  Genetically, these individuals have classic CF, but 
were phenotypically indistinguishable from the remainder of the cohort, which had either 
1 or 0 CFTR mutations.  Linkage studies of the CFTR locus in two pedigrees with 
elevated sweat chloride levels revealed CFTR was not causative of their atypical 
phenotype. Furthermore, CFTR specific chloride transport in the nasal epithelium was 




cause a CF like phenotype (genocopies).  Later studies of the same patient cohort by 
Groman helped further characterize the atypical CF phenotype (73). 
In 2005, Molly Sheridan genotyped three subunits (SCNN1A ,SCNN1B, and 
SCNN1G) of the epithelial sodium channel (ENaC) in an atypical CF cohort (74).  It had 
been previously found that this protein is regulated via direct interaction with CFTR (75, 
76). Additionally, other diseases with phenotypes overlapping atypical CF had reported 
mutations within subunits of this protein in affected patients.  These include 
pseudohypoaldosteronism type 1 (PHA1) and Liddle syndrome.  PHA1 is an autosomal 
recessive disorder characterized by renal salt wasting, elevated sweat chloride levels, 
hyponatremia, hyperkalemia, and elevated aldosterone levels.  PHA1 was linked to 
mutations in the alpha, beta, and gamma ENaC subunits in 1996 by Chang (ɑ,β) and 
Strautnieks (Ɣ) (77, 78).  PHA1 causative variants result in loss of ENaC function and 
salt-wasting, and thus these patients are treated with salt supplementation (79).  Liddle 
syndrome is associated only with mutations in the beta subunit of ENaC (SCNN1B) (80).  
Unlike PHA1, these mutations result in a gain of ENaC function, and patients are treated 
with a low salt diet.  In Sheridan’s paper, she found that additional unreported mutations 
within SCNN1B were causative of an atypical CF phenotype (74).  However, only 2 of 
the 20 patients studied carried causative variants, suggesting that additional unidentified 
loci may be causative of this phenotype. 
As part of my thesis work, I have sought to elucidate possible causative genes for 
atypical CF phenotypes through exome and whole genome sequencing analysis.  Many of 
the families originally reported by Molly Sheridan and Joshua Groman were included in 




CFTR, few candidates currently have compelling genetic or biological evidence to 
warrant functional studies.  In Chapter 2, I will discuss the discovery and molecular 
evaluation of variants within carbonic anhydrase 12 (CA12) in a family presenting with 
elevated sweat chloride levels and hyponatremic dehydration due to salt wasting.  This is 
one of several exome sequencing analyses I conducted which resulted in determination of 
the molecular etiology of an atypical CF phenotype.    
Next Generation Sequencing Analysis 
 Both chapters of this thesis heavily relied on a technology which steadily grew in 
popularity during my graduate studies: next generation sequencing (NGS).  This 
massively-parallelized approach to genomics has had a profound influence on our ability 
to discover and understand variation in large populations, across cell and tissue types, and 
among species.   
 Chapters 2 and 3 utilize a targeted approach to sequencing regions of interest (as 
opposed to “shotgun” sequencing, often used for whole genomes).  Very generally in this 
approach, a genomic DNA sample is first sheared into small fragments (~300-800bp).  
Next, a small adapter sequence is ligated to each end (~50bp).  This adapter sequence 
contains a barcode and can be used to identify a given sample preparation.  During 
capture, the prepared gDNA is hybridized with bait sequences (previously designed based 
on known regions of interest).  These baits are often biotinylated such that, after 
hybridization with the DNA, they can be pulled down used streptavidin coated beads.  
This process allows one to then wash away the undesired DNA sequences.  Following 




the library.  Finally, the library can be run through a flow-cell on an NGS platform such 
as Illumina’s HiSeq.  Illumina utilizes “sequencing by synthesis”.  In this process, 
fluorophore-tagged nucleotides are washed over the library which has been immobilized 
to the surface of a flow cell via the adaptor sequences and amplified.  If a nucleotide is 
incorporated into a growing sequence of DNA (“synthesis”), it will emit light which is 
captured by the photodetector.  This photodetector tracks each growing strand of DNA, 
monitoring which bases have been incorporated.  The photodetector then conveys this 
signal to a computer, which processes the signal and generates a sequencing “read”.  The 
read contains two pieces of information: the ACTG sequence of the read, and a 
confidence score associated with that call.   These reads can then be analyzed by 
bioinformatics software downstream (e.g. alignment, variant calling).   
 The majority of my studies have been devoted to developing and optimizing the 
post-sequencing processing of NGS data.  There are three key steps in the process:  read 
mapping or alignment, variant calling, and variant annotation.  The methods which can be 
used at these steps are highly variable.  The techniques employed must be carefully 
constructed and optimized to the type of assay (whole genome, exome, targeted, RNA, 
etc.), and the downstream analysis (research vs. clinical, desired sensitivity/specificity, 
filtering or burden testing).   
Briefly, alignment is the process by which reads are mapped back to a known 
reference sequence.  This is the most popular approach in human samples because the 
reference is well annotated, and the process is relatively quick.  Alternatively, a de novo 
alignment can be performed where reads are aligned into contigs without the use of a 




types of RNA studies).  There are many alignment software currently available, all of 
which have their pros and cons.  In my studies, I have used “gapped” aligners, which 
allow for insertions and deletions within the reads (81, 82).  The initial alignment is often 
optimized through a variety of steps including marking of duplicate reads and local de 
novo alignment in regions of high variability (often around insertions or deletions) (83).   
Both small and large variants can then be called from the alignment (and are often 
informed by the unmapped reads).  Variant callers are perhaps even more abundant than 
aligners, and again, each has its own pros and cons.  There is marked discordance 
between calls from competing software (84).  In order to reduce the fraction of false 
positive calls in my dataset, I have incorporated up to 5 variant callers into my pipelines.  
A final call set is then generated from the majority call (i.e. requiring 3 out of 5 software 
to be concordant for a given call).  However, it is difficult to assess the accuracy of this 
final call-set, which may have a high false negative rate, given the lack of a consensus 
truth set at the time of its development.  Finally variants can be annotated with meta-data 
such as conservation and allele frequency.   This can be done using popular software 
(85), or using custom scripts in combination with public repositories.   
The downstream analysis of these datasets is really where the NGS field is 
currently exploring and growing.  Much of my thesis work has been spent writing scripts 
to correctly conduct these analyses.  As time progresses, more methods will become 
available, allowing for more rapid and diverse processing of this data.  Additionally, as 
these advanced analyses become more popular, a larger community will be available, 




 Next generation sequencing allowed me to pursue many scientific hypotheses 
during my studies – two of which are highlighted in this thesis.  In Chapter 2, exome 
sequencing of one pedigree and one unrelated proband was employed in order to 
elucidate disease causing variants associated with their rare phenotype.  In Chapter 3, a 
custom designed targeted resequencing capture was used to study variation in cis with the 




















Loss of carbonic anhydrase XII function in individuals with 













Briana Vecchio-Pagán; Melissa Lee; Neeraj Sharma; Abdul Waheed; Xiaopeng Li; Karen S. 
Raraigh; Sarah Robbins; Sangwoo T. Han; Arianna L. Franca; Matthew J. Pellicore; Taylor A. 
Evans; Kristin M. Arcara; Hien Nguyen; Shan Luan; Deborah Belchis; Jozef Hertecant; Joseph 






Elevated sweat chloride levels, failure to thrive (FTT), and lung disease are 
characteristic features of cystic fibrosis (CF, OMIM #219700). Here we describe variants 
in CA12 encoding carbonic anhydrase XII in two pedigrees exhibiting CF-like 
phenotypes. Exome sequencing of a white American adult diagnosed with CF due to 
elevated sweat chloride, recurrent hyponatremia, infantile FTT and lung disease 
identified deleterious variants in each CA12 gene: c.908-1 G>A in a splice acceptor and a 
novel frameshift insertion c.859_860insACCT. In an unrelated consanguineous Omani 
family, two children with elevated sweat chloride, infantile FTT, and recurrent 
hyponatremia were homozygous for a novel missense variant (p.His121Gln). Deleterious 
CFTR variants were absent in both pedigrees. CA XII protein was localized apically in 
human bronchiolar epithelia and basolaterally in the reabsorptive duct of human sweat 
glands. Respiratory epithelial cell RNA from the adult proband revealed only aberrant 
CA12 transcripts and in vitro analysis showed greatly reduced CA XII protein. Studies of 
ion transport across respiratory epithelial cells in vivo and in culture revealed intact 
CFTR-mediated chloride transport in the adult proband. CA XII protein bearing either 
p.His121Gln or a previously identified p.Glu143Lys missense variant localized to the 
basolateral membranes of polarized MDCK cells, but enzyme activity was severely 
diminished when assayed at physiologic concentrations of extracellular chloride. Our 
findings indicate that loss of CA XII function should be considered in individuals without 






Persistently elevated sweat chloride concentration caused by loss of function 
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene is the 
diagnostic hallmark of cystic fibrosis (CF). Individuals with features of CF who do not 
carry any disease-causing CFTR alleles have been reported. These patients were 
phenotypically indistinguishable from CF patients carrying two known CF-causing 
mutations (72). Some individuals presenting a milder, atypical CF were found to carry 
variants that altered the function of subunits that form the epithelial sodium channel 
(ENaC) (74),(73). 
CA12, the gene encoding carbonic anhydrase (CA) XII, has been implicated as a 
cause of elevated sweat chloride concentration, failure to thrive in infancy, and recurrent 
hyponatremia in two consanguineous Bedouin kindreds (86),(87). The same missense 
variant was identified in both pedigrees.  However, the variant caused only a modest 
reduction (~30%) in enzymatic activity (87), which was unexpected as autosomal 
recessive disorders are generally associated with severe loss of function variants. The 
authors speculated that the minimal reduction in CA XII function produced a phenotype 
limited to the sweat gland (OMIM #143860) (87),(88).  
In this study, we report the discovery and analysis of loss of function variants in 
CA12 that associate with elevated sweat chloride concentrations in two unrelated 
pedigrees. An adult proband in one pedigree also displayed pulmonary features that 
overlap with CF; namely recurrent pulmonary exacerbations, Pseudomonas in sputum 




These findings indicate that loss of CA XII activity is uncompensated in certain epithelia 
and that CA XII may play a key role in the function of the pulmonary airways as well as 
the sweat gland. 
Results 
Identification of CA12 variants segregating in two unrelated pedigrees 
The proband in pedigree A (II:1, Figure 2.1A) presented with failure to thrive at 
2.5 months of age and sweat chloride concentrations ranging from 82 to 88 mEq/L. She 
was diagnosed with cystic fibrosis (CF) and prescribed pancreatic enzymes to improve 
growth. At 7 months of age she had an episode of hyponatremic dehydration requiring 
hospitalization (plasma sodium 120 mm/L upon admission). Spirometry from ages 7-9 
years indicate three episodes of airway obstruction, with forced expiratory volumes 
(FEV1) and forced expiratory flows (FEF25-75%) falling below 80%. At age nine, repeat 
sweat chloride testing revealed elevated levels (range=112-116 mEq/L) and serum IRT 
levels were within normal range, resulting in the discontinuation of pancreatic enzymes. 
Nasal potential difference (NPD) testing performed at this time reported aberrant chloride 
transport consistent with CF. It should be noted that NPD testing can have considerable 
technical variability and was standardized after this test was administered to proband A. 
Available clinical records between the ages of 19-22 revealed a persistent cough and 
cultures of bacteria common to CF patients, including Pseudomonas aeruginosa in the 
throat (age 19), Stenotrophamonas maltophilia in the throat (age 20), and Pseudomonas 
fluorescens in sputum (age 22). The proband’s pulmonary exacerbations were often 




antibiotics, and steroids. At age 25, NPD testing repeated at the same clinical facility was 
not consistent with CF (response to low chloride and isoproterenol: -24 mV on right and -
16 mV on left). The proband continued to be seen regularly at an accredited CF care 
center and reported compliance with daily respiratory treatments including aerosolized 
albuterol, acetylcysteine, hypertonic saline, and chest physiotherapy. High resolution 
chest CT scanning revealed mild bronchiectasis without scarring, inflammation, or mucus 
plugging (Figure 2.2). Assessment of airway dilatation was confirmed by two adult CF 
pulmonologists and an additional interpretation by a radiologist who was masked to the 
clinical status of proband A. The proband has also been treated by a dermatologist for 
axillary hyperhidrosis. Exome sequencing was performed on the proband, her unaffected 
sister, and both parents. Average depth of coverage was 87X, and 93.2% of the targeted 
regions were covered at a depth ≥ 10X. No deleterious variants were found in CFTR or 
the three genes (SCNN1A, SCNN1B, and SCNN1G) that encode the epithelial sodium 
channel (ENaC). Loss of ENaC function can cause pseudohypoaldosteronism, a 
secondary and rare cause of elevated sweat chloride concentration (74),(89). Two 
variants within CA12 were discovered in trans (compound heterozygosity) in the proband 
(II:1): a variant inherited from her father (I:1) in the canonical splice acceptor site of exon 
10, c.908-1 G>A (rs148438059, chr15:63,619,433, ClinVar accession# SVC000255965) 
and an insertion variant of four nucleotides inherited from her mother (I:2), 
c.859_860insACCT (chr15:63,631,029-63,631,030, ClinVar accession# SVC000255963) 
in exon 8. The splice acceptor variant is found in heterozygosity in 53 individuals in the 
Exome Aggregation Consortium (ExAC) variant browser (90) with a global MAF of 




The proband’s insertion mutation was not found in ExAC. CA12 variants were confirmed 
in all family members via Sanger sequencing. 
In a second unrelated family, a six year old Omani boy (proband B, II:3, Figure 
2.1B) presented with a history of hyponatremic dehydration, elevated sweat chloride, and 
bilateral hyperkeratosis of the heels. Hyponatremic dehydration was alleviated with 
administration of Pedialyte and unrestricted access to dietary salt. Four sweat chloride 
measurements ranged from 90 to 110 mEq/L. Pulmonary function tests and fecal elastase 
measurements were within the normal ranges, ruling out chronic pulmonary and exocrine 
pancreatic insufficiency associated with CF. Aldosterone measurements excluded 
pseudohypoaldosteronism. Clinical diagnostic sequencing of the coding and intron 
flanking regions of CFTR and SCNN1A encoding the α subunit of ENaC in proband B did 
not detect sequence variations predicted to be deleterious. An 11 year old sister (II:1) of 
proband B initially considered to be asymptomatic was discovered to have a sweat 
chloride of 130 mEq/L. At a two year follow up, this sister was found to have developed 
a phenotype concordant with that of proband B, reporting episodes of hyponatremic 
dehydration as well as mild bilateral hyperkeratosis of the heels. Hyperkeratosis of the 
heels was not observed in proband A or the previously reported patients (88) and could 
be due to unrelated deleterious recessive alleles that may be present in this 
consanguineous pedigree. Unaffected siblings in pedigree B had sweat chloride 
measurements within the normal range for the referring laboratory (<50 mEq/L, personal 
communication Jozef Hertecant). No evidence of respiratory disease was reported in 
either patient; however, we were unable to obtain high resolution chest CT scans. 




no pulmonary testing of any kind. CFTR, SCNN1B, and SCNN1G were excluded via 
genetic linkage analysis of all individuals in pedigree B with the assumption of recessive 
inheritance. Exome sequencing was conducted on proband B, his affected sister, and all 
unaffected siblings in pedigree B. The average depth of coverage was 34X, and 62.5% of 
the targeted regions were covered at a depth ≥ 8X. A previously unreported variant c.363 
C>A (chr15:63,637,742, ClinVar accession# SVC000255964) in exon 4 of CA12 was 
found in homozygosity only in the two affected individuals (Figure 2.1B). It is predicted 
to cause a substitution of His at codon 121 with Gln (p.His121Gln). Segregation of the 
CA12 c.363 C>A variant in an autosomal recessive inheritance pattern was confirmed in 
all family members in pedigree B via Sanger sequencing. 
CA XII is localized to the basolateral membrane of ductal epithelia in sweat gland and 
apical membrane in airway epithelia.  
To ascertain whether CA XII was expressed in the organs affected in the two 
probands, namely the sweat gland and the airways, immunohistochemistry (IHC) of 
normal skin and lung sections was performed. IHC of whole skin tissue showed robust 
sweat gland expression of CA XII in the basolateral compartment of the reabsorptive 
ductal cells (Figure 2.3B, 2.3C). Basolateral CA XII staining in the reabsorptive sweat 
duct was distinguishable from apically localized CA II, a ubiquitously expressed 
cytosolic carbonic anhydrase (Figure 2.3D, 2.3E). To determine if CA XII is expressed 
in the airways, IHC of lung was performed and showed robust apical localization of CA 
XII in bronchiolar epithelia (Figure 2.3F, 2.3G). Of note, IHC of CA XII in the lung was 
performed using the same anti-CA XII antibody (ProteinTech #15180-1-AP) that was 




(basolateral within the sweat gland; apical within bronchioles), may indicate alternative 
roles for this protein in reabsorptive or secretory epithelial membranes.  
The c.908-1 G>A and c.859_860insACCT variants found in proband A generate aberrant 
RNA transcripts 
The two variants identified in proband A were predicted to affect RNA 
processing. To evaluate this supposition, respiratory epithelia from the inferior nasal 
turbinate was obtained for RNA and functional studies. CA XII is expressed in nasal 
epithelial cells (Supplemental Table 2.1) and respiratory epithelia of the nasal turbinates 
have been used as a proxy for respiratory epithelia of the airways (91). The CA12 gene is 
composed of 11 exons that constitute its primary mRNA transcript (Figure 2.4A). 
Alternative splicing of CA12 has been observed in native and cancerous tissues by both 
RT-PCR and RNA sequencing (92). The most common alternative isoform of CA12 
(CCDS# 10186) removes exon 9, a small exon composed of 33 bp, allowing the 
downstream transcript to retain the same reading frame. A review of publicly available 
RNA-sequencing splicing data from the Human Protein Atlas (93) reveals this isoform is 
predominately expressed in brain, and select other tissues (Supplemental Table 2.1). 
Two additional rare isoforms of CA12 result from skipping of exons 9 and 10, or exon 10 
only. These alternative CA12 transcripts are of very low abundance in nasal and bronchial 
epithelial cells compared to the full-length transcript with 11 exons. PCR of cDNA 
derived from nasal epithelial cell RNA of proband A generated DNA products of 1069 
bp, 980 bp, and 947 bp. Each product was gel purified and subject to Sanger sequencing. 
The 1069 bp product corresponded to full-length CA12 transcript bearing the insertion 




incorporation of 49 novel residues following codon 287 and a premature termination 
codon (PTC) in exon 11 (predicted size 336 residues; Figure 2.4B). Despite the presence 
of a PTC, the transcript was stable due to the location of the PTC in the last exon of 
CA12, thereby allowing the transcript to evade nonsense mediated RNA decay (94). The 
splice site variant found in proband A, c.908-1 G>A, was predicted to cause misplicing of 
CA12 exon 10 as it alters an invariant nucleotide of the canonical 3’ splice acceptor site. 
Indeed, the 980 bp amplicon was CA12 transcript missing exon 10 and the 947 bp 
product was an alternatively spliced CA12 transcript missing exons 9 and 10 (Figure 
2.4C). Loss of exon 10 was predicted to result in a frameshift beginning at codon 302 and 
translational read-through of the native termination codon. A novel termination codon in 
the 3’ UTR occurs at amino acid position 413. The resulting protein is predicted to be 
composed of the first 302 amino acids of CA XII followed by 111 novel residues, 89 of 
which are translated from the 3’ UTR. Skipping of exons 9 and 10 would add the same 
111 novel residues but the frameshift would start at codon 291 (predicted size 402 
residues). Finally, amplification from exon 8 to exon 10 and Sanger sequencing verified 
that all transcripts bearing exons 9 and 10 contained the c.859_860insACCT insertion 
(data not shown). In summary, all CA12 mRNA transcripts in the nasal epithelial RNA of 
proband A were abnormal and each was predicted to generate aberrant CA XII protein. 
CA12 variants found in proband A generate unstable CA XII protein  
Expression vectors with CA12 cDNA modified to correspond to each of the three 
transcripts observed in the nasal epithelial cells of proband A, the missense variant 
p.His121Gln (c.363 C>A) observed in proband B, and a previously described Bedouin 




lysates were subjected to analysis by Western blot. Wild-type (WT) CA XII was present 
in both unglycosylated (39 kDa) and fully glycosylated (43 kDa) forms (95) (Figure 2.5, 
lane 2). CA XII protein was severely reduced in the lysate of cells transfected with CA12 
expression vectors bearing the insertion variant c.859_860insACCT (7.2%-13.3% of WT) 
and only a single band of the predicted mass of the unglycosylated protein (37.9 kDa) 
was observed (Figure 2.5, lane 4). CA XII lacking residues encoded by exon 10 and 
exons 9 and 10 were barely visible (Figure 2.5, lanes 5, and 6). CA XII bearing the 
missense variants p.His121Gln, and p.Glu143Lys generated protein of a molecular mass 
comparable to WT and unglycosylated and glycosylated forms were observed (Figure 
2.5, lanes 7 and 8). CA XII with p.Glu143Lys had a higher fraction of unglycosylated 
protein, suggesting a possible effect of the amino acid substitution on processing and 
post-translation modifications. These results indicate that each of the changes in amino 
acid composition due to the CA12 variants found in proband A cause substantial 
instability in CA XII. 
Nasal respiratory epithelial cells from proband A demonstrate CFTR-mediated chloride 
transport 
Cultured epithelial cells from proband A and controls were mounted in Ussing 
chambers for short circuit current measurements. To increase the driving force for 
chloride secretion through CFTR, the apical membrane was hyperpolarized by 
administration of amiloride that inhibits sodium current conducted by epithelial sodium 
channels. To specifically examine chloride currents mediated by CFTR, calcium-
activated chloride channels were inhibited by DIDS (4, 4’-diisothiocyanoto-stilbene -2, 




in any sample.  CFTR was activated by elevating cellular levels of cAMP with forskolin 
and 3-isobutyl-1-methylxanthine (IBMX). Upon treatment with forskolin and IBMX 
(“F+I”), the change in CFTR-mediated chloride transport in nasal epithelia from proband 
A (9.34 and 9.15 uA/cm2) were higher than that observed in nasal epithelial from a CF 
subject tested concurrently (2.1 uA/cm2). The values in proband A are consistent with 
short circuit measures of nasal epithelia from other non-CF and CF subjects (96). 
Substantial reduction in the current of cells from proband A upon addition of GlyH-101 (-
18.8 and -21.5 uA/cm2) is consistent with the chloride secretion being mediated by 
CFTR. Together, these findings suggest that loss of CA XII does not ablate CFTR-
mediated chloride secretion across nasal respiratory epithelia. 
p.His121Gln and p.Glu143Lys mutations cause near complete loss of enzyme activity of 
CAXII.  
As the missense variants permitted the generation of stable full-length protein, 
immunocytochemistry and confocal microscopy was utilized to test whether either 
variant affected the subcellular localization of CA XII. Expression in polarized epithelial 
Madin-Darby canine kidney (MDCK) cells revealed that WT CA XII localized to 
basolateral membranes (green, n=7, Figure 2.6, left panel). CA XII bearing p.His121Gln 
(green, n=8, Figure 2.6, middle panel) and p.Glu143Lys (green, n=13, Figure 2.6, right 
panel) showed basolateral localization indistinguishable from that of WT CA XII. 
Comparable staining patterns were observed when immunocytochemistry was performed 
with alternative CA XII antibodies (rabbit: Sigma Prestige; mouse: Novus) that detected 
different extracellular CA XII epitopes (data not shown). Since the p.His121Gln and 




variant on CA function by measuring carbonic anhydrase enzyme activity. Carbonic 
anhydrase activity is the reversible rate of CO2 hydration. When assayed in a 2 mM NaCl 
solution, the activity of CA XII bearing p.His121Gln is reduced by 84.6 ± 3.6% 
compared to WT (n=11) while the enzymatic activity of CA XII with p.Glu143Lys is 
reduced by 24.4 ± 4.9%, consistent with the approximate 30% reduction in activity 
previously reported under the same conditions (87) (Figure 2.7). When assayed at 
physiological salt concentrations, the enzyme activity of p.His121Gln was reduced by 
99.2 ± 0.5% compared to WT, and the activity of the p.Glu143Lys mutant was reduced 
by 97.1 ± 1.2% compared to WT (n=9) (Figure 2.7). The enzyme activities of 
p.His121Gln and p.Glu143Lys were not statistically different (p = 0.12; t test) when 
assayed in the presence of 100 mM NaCl. These findings reveal a chloride-sensitive 
abolition of carbonic anhydrase enzyme activity for CA XII p.His121Gln and 
p.Glu143Lys mutants compared to WT. 
Discussion 
Each of the CA12 variants reported in the three individuals described here with 
elevated sweat chloride, recurrent hyponatremia and failure to thrive in infancy cause 
severe loss of CA XII activity. The two variants found in proband A generate mRNA 
transcripts that are missing nucleotides that form transmembrane domains and enable 
dimerization via a key glycine zipper motif (95). Translation of cDNA that replicate the 
mRNA transcripts identified in proband A generated unstable protein products in 
heterologous cells. On the other hand, CA XII proteins bearing the missense variant 
found in this study and the previously reported missense variant were stable and, in each 




XII location in kidney cells (97). Point mutation energy modeling by FoldX suggested 
that both missense variants should affect CA XII structure and catalytic function. 
Modeling indicated that the secondary amine of histidine 121 is essential for tetrahedral 
coordination of the zinc ion within the catalytic domain. In the WT conformation, the 
H121–zinc bond distance is ~2.1Å (Supplemental Figure 2.1). When mutated to 
glutamine as in p.His121Gln, the distance from zinc to the hydroxyl of the carboxyl 
group is 3.042Å. This increased distance likely precludes formation of a coordinating 
bond, and the zinc ion is instead coordinated by a free hydroxide ion (red sphere). In the 
extracellular aqueous environment, this coordination would only be transient, potentially 
leading to poor catalytic activity. The distances of other residues, such as the highly 
conserved second shell glutamic acid 143, are also altered by p.His121Gln by a 
magnitude similar to that reported in previous studies of the Bedouin p.Glu143Lys 
mutation (86). CA XII bearing the p.Glu143Lys mutation was particularly sensitive to 
inhibition by chloride, as previously reported (87). Given that the active site of CA XII 
lies on the extracellular face of the basolateral compartment in the sweat duct, enzymatic 
activity of both mutants was assayed in the presence of increasing NaCl concentrations. 
The concentration of NaCl which most closely mimics the enzyme’s native physiological 
environment is 100 mM NaCl (98). At this concentration, catalytic activity of CA XII 
bearing each missense mutation was reduced to less than 3% of WT activity. As the 
affected individuals are homozygous for the CA12 missense mutations, it is reasonable to 
conclude that the sweat gland dysfunction observed in each is due to near complete loss 
of CA XII activity. This conjecture is supported by the studies of proband A, where 




Robust expression of CA XII in lung epithelia and the observation of 
bronchiectasis in proband A suggest a role for this protein in the maintenance of airways. 
Elevated sweat chloride concentration indicates aberrant chloride transport in the sweat 
duct and is a consistent feature of the three individuals carrying the loss of function CA12 
variants reported here, as well as in 11 individuals homozygous for the p.Glu143Lys 
mutation reported previously (88). However, CFTR-mediated chloride transport appeared 
to be intact in the nasal respiratory epithelia as determined by in vitro and in vivo 
methods, suggesting that other pathways of ion transport in the airways might be 
disrupted by the loss of CA XII. Given the importance of CAs in the maintenance of pH 
via bicarbonate metabolism, the mechanism underlying airway damage could be related 
to aberrantly low pH of airway surface liquid (ASL) due to loss of bicarbonate production 
or transport. The pH of the ASL has been shown to be integral to the proper expansion 
and processing of mucins which play a key role in CF-related bronchiectasis (99). 
Alternatively, the bronchiectasis observed in proband A might be unrelated to the loss of 
CA XII function. Spirometry measurements in all tested individuals homozygous for the 
p.Glu143Lys mutation were reported as normal (88) and chest X-rays of proband B were 
reported to be normal at age 11; however, lung function measures and chest X-rays were 
also normal throughout the life of proband A up to her current age of 25. Detection of 
abnormal airway dilatation in proband A required high resolution CT scanning; therefore, 
it is possible that bronchiectasis remains undetected in the previously reported patients 
with loss of CA XII function and the affected individuals in pedigree B. Without 
comparison chest CTs from the affected individuals in pedigree B, it cannot be 




observed in proband A. Further, if loss of CA XII function does lead to bronchiectasis, 
the possibly ameliorating impact of CF-specific airway treatments is an important 
question. Proband A has undergone routine airway clearance, therapies, and antibiotic 
courses since being diagnosed with CF as an infant. It is possible that a lifetime of 
diligent pulmonary monitoring and treatments managed by an accredited CF care center 
minimized the effect of bronchiectasis upon pulmonary function. However, estimating 
the impact of respiratory therapy on degree of airway dilatation is difficult without study 
of additional CA XII-deficient individuals manifesting pulmonary disease. Indeed, the 
identification of additional individuals with loss of CA XII function and high resolution 
chest CT scanning will clarify the role of CA XII in the airways. Given the strong 
causative connection between aberrant chloride transport and bronchiectasis in CF, CA 
XII loss of function should be considered as a potential explanation for non-CF 
bronchiectasis. 
Loss of CA XII function in a patient with respiratory disease in humans suggests a 
previously unsuspected role for this isozyme in the lung. Although each individual CA 
isozyme follows a tissue-specific expression pattern (100, 101), RNA expression studies 
show that multiple isozymes can be expressed in certain tissues (102). Loss of function of 
one isozyme may be compensated for by other isozymes in certain tissues. This 
explanation is offered for the lack of a phenotype in patients with loss of function 
mutations in CA I (103). Our findings show that isozyme redundancy does not 
compensate for loss of CA XII function in the sweat gland. Further, although other 




lung microcapillaries, our results suggest that CA XII may also play an important role in 
the maintenance of the airways. 
IHC of the sweat gland revealed CA XII to be highly expressed in the resorptive 
duct in basolateral distribution consistent with its location in other epithelia, namely 
endometrium, kidney, and large intestine (104), (105), (97). Faint staining was observed 
at the apical membrane which may be non-specific signal or evidence of dual CA XII 
localization. However, the pattern of CA XII staining was distinctly different for that of 
CA II, which was discretely localized near apical membranes of the ductal cells. CA XII 
was only found on basolateral membranes of polarized MDCK cells. In contrast, CA XII 
was discretely localized to the apical regions of normal airway. The distribution of CA 
XII does not appear to be due to non-specific signal as two antibodies that detect different 
antigenic regions of CA XII revealed the same immunolocalization pattern. Localization 
to the terminal bar is consistent with CA XII location in other tissues, including the 
bronchus and fallopian tubes (93). A possible factor in the different localization of CA 
XII could be its involvement in one of the transport metabolon complexes formed 
between CA isozymes and bicarbonate transporters that facilitate the exchange of 
bicarbonate across membranes (106). Bicarbonate transport metabolons comprised of CA 
isozymes and anion exchangers have so far been described for three of the 
transmembrane isozymes: CA IV associates with AE1 (106, 107), CA IX associates with 
AE2 (108), and CA XIV associates with AE3 (109). AE1 and CA IV have been localized 
to both basolateral and apical membranes in different cell types in the kidney (107). Since 
the kidney can absorb and secrete ions including bicarbonate, it is possible that the 




flow. However, to date, no metabolon interaction has been reported for the remaining 
transmembrane isozyme, CA XII.  
Our study suggests a mechanism for the well-established salt wasting 
complication of topiramate, a CA inhibitor and anticonvulsant commonly prescribed to 
people suffering from epilepsy. Elevated sweat chloride concentration is an established 
phenomenon observed in epileptic children being treated with topiramate (110). In these 
children, CF was clinically and/or molecularly excluded as being the cause of this 
increase in sweat chloride value, and the effect disappeared when topiramate treatment 
ended. Investigations into the inhibition potency of topiramate across the α family of CAs 
have shown that topiramate is a strong inhibitor of CA XII, and not the other 
transmembrane isozymes CA IV, IX, and XIV (111),(112). These pharmacologic 
observations are consistent with our hypothesis regarding the role of CA XII in the 
maintenance of proper ion composition in the sweat gland. Topiramate is also a strong 
inhibitor of the ubiquitous and highly active cytoplasmic isozyme CA II. 
Correspondingly, individuals being treated with topiramate have been observed to 
develop renal tubular acidosis (113), a hallmark feature of CA II deficiency syndrome. 
In summary, the individuals studied here demonstrate that severe loss of function 
mutations in CA12 cause an autosomal recessive disorder affecting chloride and sodium 
resorption in the sweat duct. The observation of airway dilatation in proband A suggests a 
possible molecular etiology for some forms of non-CF bronchiectasis, a disease that 





Materials and Methods 
Recruitment 
Family A was recruited and consented into the study Genome-wide Sequencing to 
Identify the Genes Responsible for Mendelian Disorders at Johns Hopkins University 
(IRB# NA_00045758). Family B was referred to Johns Hopkins University via private 
communication of Dr. Jozef Hertecant at Tawam Hospital, United Arab Emirates. All 
members of family A were consented into the Molecular Genetics of Cystic Fibrosis 
(IRB# NA_00050260). 
Linkage exclusion assays 
Three highly polymorphic deCODE STRs were selected for each locus to be 
excluded (CA12, and SCNN1B and SCNN1G, which lie in close proximity to one another) 
from the STS Marker track on the UCSC Genome Browser. Each marker was no more 
than 1Mb from either end of the locus to be excluded. Primer sequences from the STS 
Marker track were run through BLAT to verify specificity. Oligonucleotides were 
synthesized by IDT. Forward primers were fluorescently labeled with 6-FAM. STRs 
were PCR amplified from genomic DNA and amplification products were separated on 
an ABI Prism 3100 Genetic Analyzer by automated capillary electrophoresis. Fragment 
sizing and visualization were performed using ABI GeneMapper software. Haplotype 
phasing was performed by manual inspection. If the proband and at least one unaffected 
sibling were found to be IBD2 for a locus, it was deemed to be excluded, given an 





DNA sample acquisition, exome sequencing, and CA12 genotyping 
Peripheral blood was obtained from all consented individuals in pedigree A and 
genomic DNA was extracted by a phenol/chloroform protocol. Exome capture was 
performed on all siblings within the pedigree using the Agilent SureSelect Human All 
Exon (51 Mb), and 100 bp paired-end reads were subsequently obtained from an Illumina 
HiSeq 2500 system as part of a study within the Baylor-Hopkins Center for Mendelian 
Genomics conducted by the Center for Inherited Disease Research. Reads were aligned to 
the hg19 reference genome using Burrows-Wheeler Aligner software (115) and 
subsequent alignment processing was completed using SAMtools (116), PicardTools, and 
GATK softwares (117, 118) in a manner similar to (119). Filtering of variants was 
conducted via custom scripts, and variant prioritization was conducted using Enlis 
Genomic Research software. To verify mutations, a 654 bp region encompassing c.908-1 
G>A and c.859_860insACCT was amplified from genomic DNA from the proband A 
and her mother by PCR using the following primers (IDT): 5’F 
GCCCTGTACTGCACACACAT and 3’R AGGATGATGCCCAGACTCAG. PCR 
products were purified using QIAquick PCR purification kit (Qiagen), and then 
sequenced using the Applied Biosystems 3730xl DNA Analyzer. The resulting sequences 
were analyzed via the Sequencher analysis suite (Gene Codes). Genomic DNA extracted 
from peripheral blood was obtained from all consented individuals in pedigree B. Exome 
capture was performed on all siblings using the Illumina Truseq Exome Enrichment kit 
(62 Mb), and 90 bp paired-end reads were subsequently obtained from an Illumina HiSeq 
2000 system (Otogenetics). Exome sequencing data analysis was conducted in a manner 




software (120). CA12 (RefSeq# NM_001218.4) mutations and mode of inheritance were 
verified via Sanger sequencing. A 475 bp region encompassing c.363 C>A was amplified 
from genomic DNA of all siblings in pedigree B by PCRs using the following primers 
(IDT): 5’F GTCCCATGCTCTGGTGTTATC and 5’R 
CTTTCCAAGGTGAACCAAGAA. PCR products were purified, sequenced, and 
analyzed as described for pedigree A. The resulting sequences were analyzed via the 
Sequencher analysis suite (Gene Codes). 
It should be noted that all variant nomenclature is specific to CA12 nucleotide and 
CA XII amino acid numbering and represent the minus strand sequence unless otherwise 
specified. All genomic coordinates are specific to hg19. All variants discovered in this 
study have been submitted to ClinVar. 
IHC of CA XII in human sweat duct and lung 
Frozen discarded unidentified skin and lung obtained from the Division of 
Surgical Pathology, Johns Hopkins Hospital, Baltimore, MD, were embedded in Optimal 
Cutting Temperature (OCT) compound and held at -70°C prior to sectioning. Six µm 
cryo-sections were mounted onto uncoated microscope slides. Staining with H&E 
(Sigma, St Louis, MO, USA) for 1 min was performed for morphological evaluation. The 
rest of the slides were stored at -70°C until use. Sections were fixed for 10 min in pre-
cooled acetone followed by 5 min peroxidase block at room temperature to quench the 
endogenous peroxidase activity. Sections were further incubated in serum-free protein 
block (Dako # X0909) for 20 min at room temperature and incubated overnight at 4oC 




anti-rabbit CA2 (LSBio # C138796). Relevant universal negative control antibodies: 
mouse (Dako # N1698) and rabbit (Dako # IR600) were used to ascertain nonspecific 
staining. After washing, staining was performed using EnVision+System-HRP (AEC) kit 
from Dako (# K4008). Sections were covered with peroxidase-labeled polymer for 30 
mins. For visualization of the reaction, sections were developed in AEC+substrate-
chromogen for 5-20 mins. After washing, the sections were counterstained with 
hematoxylin (Dako # S3309) for 30 seconds, cleared, and mounted on Faramount 
aqueous mounting medium (Dako # S3025). Samples were analyzed under an Olympus 
BX51 microscope. 
Nasal epithelial culture and Ussing chamber studies 
Nasal epithelia from the proband of pedigree A were expanded and cultured using 
previous described method (121). Cells were mounted in Ussing chambers and studied as 
previously described (122). Apical and basolateral chambers contained the same bathing 
solution with symmetrical Cl- concentrations. CFTR-mediated Cl- current were measured 
using a previously described protocol (122). 
Identification of CA12 mutant transcripts 
RNA was isolated from expanded nasal brushings of proband A by standard 
Trizol-chloroform method. cDNA was made using RT-PCR (Qiagen iScript) and served 
as template for CA12 amplification. PCR products of CA12 transcript isoforms were 





Development of mutant CA12 expression vectors 
Full length wild-type (WT) CA12 cDNA in bacterial pBS II expression vector was 
generously provided by Dr. William Sly. The proband B variant c.363 C>A 
(p.His121Gln) was introduced into full length WT CA12 cDNA in bacterial pBSII 
expression vector using the QuikChange II XL Site-Directed Mutagenesis kit reagents 
and protocol (Agilent). Mutagenesis products were confirmed by Sanger sequencing. 
Each cDNA was removed from the bacterial expression vector using restriction enzymes 
KpnI and BamHI, purified by gel electrophoresis, and ligated into the eukaryotic 
pcDNA5 FRT expression vector. Subcloning was confirmed by Sanger sequencing. 
Proband A variant c.859_860insACCT was introduced into pcDNA5 FRTexpression 
vector bearing CA12 cDNA using the QuikChange II XL Site-Directed Mutagenesis kit 
reagents and protocol (Agilent). A previously described CA12 missense variant, c.427 
G>A (p.Glu143Lys), deemed a moderate hypomorph and reported in a large 
consanguineous Bedouin kindred manifesting a highly similar phenotype (87), (86) was 
also introduced into the full length CA12 cDNA. To replicate the consequences of the 
splice acceptor variant c.908-1 G>A found in proband A, CA12 cDNAs lacking exon 10 
and lacking exons 9 and 10 were custom synthesized (GeneWiz, South Plainfield, NJ). 
Since exon 10 skipping was predicted to result in a frameshift and subsequent 
readthrough of the natural termination codon, 287 bp of the CA12 3’ UTR were included 
in each construct. Both constructs were removed from the bacterial pUC57 expression 
vector using restriction enzymes KpnI and EcoRV, purified by gel electrophoresis, and 





Expression of WT CA XII and mutant proteins in HEK293 cells 
HEK293 cells were transiently transfected with 500 ng of WT and mutant CA12 
vectors using Lipofectamine 2000 Reagent and standard protocol (Invitrogen). Cells were 
lysed 24 hours post-transfection. Western blotting of cell lysates was performed using 
anti-CA XII antibody (Novus #NBP1-81668), and loading control GAPDH antibody 
(Sigma #G9545). 
Immunocytochemistry of CA XII in a polarized epithelial cell line 
Madin-Darby canine kidney (MDCK) cells were transiently transfected with 1.6 
µg of CA12 cDNA using 3.2 µl Lipofectamine 2000 Transfection Reagent and protocol 
(Invitrogen). Cells were fixed one day post-transfection with 4% paraformaldehyde for 
20 mins and rinsed with 1X PBS. Cells were permeabilized with 0.5% Triton X-100 for 5 
mins, then rinsed with 1X PBS, and blocked overnight at 4C with 2.5% goat serum. Cells 
were immunostained using rabbit anti-CA XII primary antibody (ProteinTech #15180-1-
AP) diluted 1:200 and anti-ZO1 primary antibody (Invitrogen) with a conjugated anti-
mouse red fluorophore diluted 1:200, followed by incubation in anti-rabbit secondary 
antibody diluted 1:50. Findings were validated by staining with different primary anti-CA 
XII antibodies from Sigma Prestige (mouse) and Novus (rabbit). All antibodies were 
diluted in 2.5% goat serum blocking solution. Cells were washed in 1X PBS three times 
for 10 mins following the 90 mins primary antibody incubation. Cells were washed in 1X 
PBS four times for 15 mins following the 30 mins secondary antibody incubation. Cells 




Reagent with DAPI and viewed with the Zeiss LSM510-Meta single-point confocal laser-
scanning microscope and Zen imaging software. 
Carbonic anhydrase enzyme activity assay 
Cell pellets were lysed by sonication in 300 µl lysis buffer (PBS containing 
protease inhibitors, 1 mM each of PMSF, o-phenanthroline, EDTA, benzamidine-
hydrochloride and iodoacetamide plus 1% NP-40) and left on ice. The media were 
centrifuged to remove dead cells. The protein concentration of cell lysates was 
determined by microLowry's procedure using bovine serum albumin as a standard (123). 
The carbonic anhydrase activity was determined using Maren's procedure (124) as 
described (125). To reflect extracellular physiological chloride concentration (98), 100 
mM NaCl was utilized. 
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Figure 2.1. Segregation of putative deleterious CA12 variants in two unrelated 
families. Filled shapes indicate status as affected and arrows indicate the proband in each 
family. The ages indicate the age of the individual at the time of exome sequencing. (A) 
Pedigree A: A white American family in which the proband exhibits consistently elevated 
sweat chloride concentration and bronchiectasis. The proband carries a splice acceptor 
variant c.908-1 G>A and an insertion frameshift variant c.859_860insACCT. (B) 
Pedigree B: An Omani family with first-cousin parents as indicated by the double 
horizontal line. The proband and affected sister exhibit elevated sweat chloride 
concentrations and have experienced multiple episodes of hyponatremic dehydration. 






Figure 2.2. Axial plane high resolution CT images of proband A. Examples of 
enlargement of the airways (tram-tracking and signet rings) are indicated by red arrows. 
This bronchiectasis is seen in the absence of mucus plugging, scar tissue, or surrounding 
inflammation. It is unknown as to whether this mild pulmonary phenotype would be more 
exacerbated had the proband not been undergoing daily preventative lung therapies 








Figure 2.3 Immunohistochemical staining of CA XII and CA II in human skin and 
lung. (A) Diagram depicting longitudinal view of sweat gland components with red line 
indicating a hypothetical plane used to generate slices for the micrographs shown in 
panels B, C, D, E. (B) Two populations of sweat gland resorptive ducts (“RD”) and 
secretory coils (“SC”) immunostained for CA XII and counter-stained with hematoxylin 
and eosin. The resorptive ducts (n=9 different cross-sections captured in this panel) show 
positive staining for CA XII in a two cell thick layer of cuboidal epithelia cells. The 
myoepithelial cells surrounding the secretory coils (n=3 different cross-sections captured 
in this panel) show light staining of CA XII that may be non-specific. Magnification of 
this micrograph is 100x. (C) Enlargement of CA XII positive staining of the basolateral 




localized control protein CA II in sweat ducts and secretory coils. Magnification of this 
micrograph is 100x. (E) Enlargement of resorptive ducts from panel E showing apical 
localization of CA II. (F) CA XII positive staining of the luminal edge of a bronchiole 
cross-section. Magnification of this micrograph is 100x. (G) Positive staining of apically 
localized CA XII in the terminal bar of bronchial epithelia. Magnification of this 










Figure 2.4.  Effect of CA12 variants upon RNA processing in nasal epithelial cells 
from proband A. (A) Exon and intron structure of CA12 with locations of proband A 
variants identified by NGS. Rectangles represent exons and the lines through the center 
of the rectangles represent the genomic axis. Variants are indicated with triangles and 
HGVS cDNA names. The gray rectangle indicating exon 9 is spliced out in an alternative 
CA12 transcript whose function and tissue distribution is unknown. (B) (Left) 
Electropherogram of Sanger sequencing of cDNA reverse transcribed from RNA 
extracted from proband A cultured nasal epithelial. Sequencing detected a heterozygous 
insertion variant c.859_860insACCT on a transcript retaining alternatively spliced exon 
9. A second transcript detected by sequencing does not bear the insertion, retains exon 9, 
and is consistent with transcript lacking exon 10 as a result of the in trans variant c.908-1 




imperfect isolation of the similarly sized transcripts by gel purification as transcript 
bearing the insertion is only 89 bp longer than transcripts lacking exon 10 only. (Right) 
Gene models depict RNA processing of the insertion variant and the predicted gene 
product. The insertion variant causes a frameshift starting in exon 8, a premature 
termination codon in exon 11, and was predicted to generate a misfolded protein targeted 
by ERAD. Hashed rectangles indicate an altered exonic reading frame. (C) (Left) 
Electropherogram of Sanger sequencing detecting transcript missing exons 9 and 10, and 
a second transcript missing exon 10 only, due to heterozygous splice acceptor variant 
c.908-1 G>A. Imperfect isolation of transcripts in this reaction is due to alternatively 
spliced exon 9 which is only 33 bp long. (Right) Gene models depict the two processed 
RNAs and protein products lacking exon 10 observed by RT-PCR: one with exon 9 
alternatively spliced out and one retaining exon 9. This variant is predicted to cause 
skipping of exon 10, a frameshift resulting in readthrough of the native stop codon, 
translation of 267 nucleotides from the 3’ UTR, and a misfolded protein targeted by 
ERAD. Hashed rectangles indicate an altered exonic reading frame and filled rectangles 







Figure 2.5. Expression of transiently transfected wild-type and mutant CA XII 
protein in HEK 293 cells. Western blot of cell lysates extracted from HEK 293 cells 
(top) following transfection with CA XII expression vectors. Probing with anti-CA XII 
antibody (Novus) shows unglycosylated (39 kDa) and glycosylated (43 kDa) protein 
generated from transfections with WT CA12 (lane 2), c.363 C>A (lane 7) and c.427 G>A 
(lane 8). The insertion variant in proband A (c.859_860insACCT) produced a faint band 
of approximately 38 kDa while CA XII cDNA missing exon 10 and exons 9 and 10 
sequence generated only faint bands. The negative control in the first lane is a mock 
transfection. The third lane has no lysate. GAPDH loading control (bottom) shows 







Figure 2.6. Subcellular localization of WT and mutant CA XII in polarized MDCK 
cells. Fluorescent co-staining of (left) WT CA XII (green), (center) p.His121Gln (green), 
and (right) p.Glu143Lys (green) with endogenous tight junction protein ZO1 (red) and 
nuclear stain DAPI (blue) in polarized MDCK cells imaged in the xz-plane. This 
micrograph reveals primarily lateral staining of CA XII; however, basal and lateral 
staining were observed for WT (n=7 different micrographs), p.His121Gln (n=8 different 
micrographs), and p.Glu143Lys (n=13 different micrographs). The apical membrane is 






Figure 2.7. Enzymatic activity of CA XII proteins bearing p.His121Gln or 
p.Glu143Gly substitutions. Enzymatic activity of CA XII mutants p.His121Gln (red 
boxplot series) and p.Glu143Gly (blue boxplot series) was determined by assaying the 
reversible rate of hydration of CO2 as previously described in the absence (left) or 
presence (right) of physiological concentration of NaCl and normalizing to wild-type. 
Boxes represent the interquartile range (IQR) and the horizontal bars within the boxplots 
represent the median. The top whisker represents the 75th percentile plus 1.5 times the 
IQR and the bottom whisker represents the 25th percentile minus 1.5 times the IQR. 





Supplemental Figure 2.1. Computational modeling of CA XII active site. (A) Wild-
type active site showing zinc ion (teal) coordinated by three histidines (119, 121, 145) 
and hydroxide group (red sphere) stabilized by threonine 226. (B) Mutation of amino acid 
121 to glutamine leading to transient coordination of zinc by hydroxide ion and an 
increased theoretical bond distance of 3.04Å when compared to native histidine. Bond 





Supplemental Table 2.1. RNA-sequencing splice junction data shows distribution of 
CA XII isoforms in various tissues. Raw reads obtained from various tissues through 
the sequence read archive were aligned to the hg19 reference genome and splice 
junctions were detected using TopHat software. Depth indicates number of reads 
supporting each splice junction, with lower depths indicative of limited expression of 
CA12 in that tissue. Percentages relative to all splice junctions detected for this region are 
WT Ex 9 Skip
Ex 9 and 
10 skip




% Ex 9 
skip
% Ex 9 & 
10 skip
% Ex 10 
skip
Kidney 1 592 0 0 0 592 100.00% 0.00% 0.00% 0.00%
Kidney 2 454 0 2 0 456 99.56% 0.00% 0.44% 0.00%
Bronchial 
Epithelia 3
196 0 13 0 209 93.78% 0.00% 6.22% 0.00%
Skin 1 166 23 11 8 208 79.81% 11.06% 5.29% 3.85%
Fallopian Tube 27 153 2 0 182 14.84% 84.07% 1.10% 0.00%
Bronchial 
Epithelia 2
153 0 12 0 165 92.73% 0.00% 7.27% 0.00%
Colon 1 111 9 1 0 121 91.74% 7.44% 0.83% 0.00%
Panc 2 92 0 0 0 92 100.00% 0.00% 0.00% 0.00%
Skin 2 45 0 4 0 49 91.84% 0.00% 8.16% 0.00%
Nasal Epithelia 1 42 0 1 0 43 97.67% 0.00% 2.33% 0.00%
Colon 2 36 0 0 0 36 100.00% 0.00% 0.00% 0.00%
Thyroid 32 0 0 1 33 96.97% 0.00% 0.00% 3.03%
Nasal Epithelia 2 32 0 0 0 32 100.00% 0.00% 0.00% 0.00%
Panc 1 27 0 0 0 27 100.00% 0.00% 0.00% 0.00%
Small Intestine 24 0 0 0 24 100.00% 0.00% 0.00% 0.00%
Brain 1 0 12 0 0 12 0.00% 100.00% 0.00% 0.00%
Stomach 11 0 0 0 11 100.00% 0.00% 0.00% 0.00%
Cervix 2 5 0 0 7 28.57% 71.43% 0.00% 0.00%
Testes 1 3 3 0 0 6 50.00% 50.00% 0.00% 0.00%
Brain 2 0 5 0 0 5 0.00% 100.00% 0.00% 0.00%
Lung 1 2 0 0 1 3 66.67% 0.00% 0.00% 33.33%
Ovary 0 2 0 0 2 0.00% 100.00% 0.00% 0.00%
Bronchial 
Epithelia 1
1 1 0 0 2 50.00% 50.00% 0.00% 0.00%
Heart 1 0 1 0 0 1 0.00% 100.00% 0.00% 0.00%
Lymph Node 0 1 0 0 1 0.00% 100.00% 0.00% 0.00%
Lung 2 1 0 0 0 1 100.00% 0.00% 0.00% 0.00%




also included. All general tissue samples (non-epithelia) were obtained from the Human 
Protein Atlas through the SRA (ERP003613). Non-epithelia tissues are presumed to be of 
mixed cell types. Epithelia specific data were obtained from SRA studies: SRP018883, 





















Deep resequencing of CFTR in 762 F508del homozygotes reveals 
clusters of non-coding variants associated with variation in sweat 
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Extensive phenotypic variability is observed in cystic fibrosis (CF) patients 
homozygous for the common CF-causing variant F508del. To determine whether variants 
within and surrounding CFTR contribute to the phenotypic variability, we examined this 
locus in 1524 F508del chromosomes using next generation sequencing. In phase 1, 
~200kb encompassing CFTR and extending 10 kb 5’ and 5 kb 3’ of the gene was 
sequenced in 486 F508del homozygotes selected from the extremes of sweat chloride 
concentration. In phase 2, a 510 kb region which included the entire topologically 
associated domain (TAD) of CFTR was sequenced in 276 F508del homozygotes drawn 
from extremes of lung function.  An additional 163 individuals who carried F508del and 
a different CF-causing variant were sequenced to inform haplotype construction.  Region-
based burden testing of both common and rare variants revealed seven regions of 
significance (ɑ=.01), five of which overlapped known regulatory elements or chromatin 
interactions.  Notably, the -80kb locus known to interact with the CFTR promotor 
associated with variation in sweat chloride and lung function.  Haplotype analysis 
revealed a single rare recombination event (1.9% frequency) in intron 15 of CFTR 
bearing the F508del variant.  Otherwise, the majority of F508del chromosomes were 
markedly similar, with only minor variations of one ancestral haplotype observed, 
consistent with a single origin of the F508del allele. Together, these high resolution 
variant analyses of the CFTR locus suggest a role for regulatory motifs in trait variation 
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Introduction 
Cystic fibrosis (CF) is a Mendelian disease affecting >70,000 patients world-
wide.  The primary phenotypes exhibited in affected individuals include elevated sweat 
chloride levels, lung disease, and pancreatic insufficiency. The severity of these 
phenotypes in each individual is primarily determined by the CF-causing variants they 
have inherited (36).  CF variants can be classified into several groups by their expected 
functional impact on the cystic fibrosis transmembrane conductance regulator, or CFTR 
(37, 126).  The most common disease-causing variant leads to the loss of phenylalanine at 
amino acid position 508, commonly referred to as F508del (ΔF508, rs121909001).  This 
variant is present in the homozygous state in ~50% and heterozygous state in a further 
40% of CF patients (127, 128), where it results in the improper folding and eventual 
degradation of the final protein product (129).  In the absence of the CFTR protein, 
chloride and bicarbonate movement across the apical membranes of epithelial tissues is 
abnormal (130). Aberrant ion transport leads to unusually viscous secretions in the lung 
and pancreas, resulting in damage to both organ systems.  While pancreatic enzyme 




obstructive pulmonary disease is difficult to treat symptomatically and remains the 
primary cause of morbidity and mortality in CF (131). 
Treatment of CF has been revolutionized by advent of small molecule drugs that 
target defective CFTR (132, 133).  Due to the commonness of F508del, there has been 
intense effort to develop drugs that recover function of CFTR bearing F508del (134). 
However, F508del has been challenging to target as the omission of a single 
phenylalanine at codon 508 causes multiple defects in the function of CFTR.  Prime 
among these is a folding defect that prevents CFTR from achieving a stable tertiary 
structure, leading to misfolded intermediates that are degraded by ER quality control 
mechanisms (135-137).  Even when a small fraction of CFTR-F508del folds and traffics 
to the cell membrane, the resulting protein is minimally active (138, 139).  These two 
defects have been tackled by combining a ‘corrector’ compound VX-809 that rectifies 
folding and a ‘potentiator’, VX-770 that activates the chloride channel of CFTR.  The 
strategy has resulted in the recent approval in the U.S. of a combination drug 
(Orkambi™) for individuals homozygous for the F508del variant (132, 140-142).  
However, Orkambi produces only modest improvement in lung function in F508del 
homozygotes and no significant improvement in patient that have only one copy of 
F508del (132). Consequently, there has been a concerted effort to identify molecules with 
higher effectiveness for CFTR-F508del by empirical screening (143).  
To inform the search for small molecules that target CFTR-F508del, we have 
systematically investigated genetic variation in CFTR alleles bearing F508del.  Our 
overarching goal was to identify any variants or combination of variants that modify 




(R117H and poly T tract; (144)) and rare (F508del and R553Q;  (145)) intragenic 
modifiers in CFTR have previously been reported. Studies of F508del homozygotes have 
revealed a broad range of both sweat chloride values and lung function (36, 44, 45, 146).  
Affected twin and sibling studies indicate that the CFTR locus is the primary determinant 
of variation in sweat chloride concentration, accounting for 56% of total variance 
(Collaco et al, in review).  Variation elsewhere in the genome (i.e. genetic modifiers) 
appears to play a minor role in sweat variability. Variation in the CFTR gene also 
contributes to phenotypic variance in lung function but at a lower effect size (46).  Thus, 
F508del homozygotes at the extremes of the distribution of CF traits, particularly sweat 
chloride concentration, provide an opportunity to find variants that modulate the effect of 
F508del upon CFTR function.  
Identification of variants in cis with F508del that modify disease severity should 
improve our understanding of the molecular mechanisms that ameliorate the defect 
caused by the F508 variant. These findings could, in turn, inform rational design of 
molecular treatments for CF. Consequently we have performed deep re-sequencing of 
intragenic and extragenic regions surrounding CFTR in 762 F508del homozygotes.  
Region-based burden testing was used to test whether genetic variation within and near 
CFTR which is associated with sweat chloride concentration or lung function. High 
resolution haplotypes and linkage disequilibrium patterns were used to map 







Variation in CFTR chromosomes bearing F508del 
A total of 925 individuals with CF (762 F508del homozygotes and 163 F508del 
heterozygotes) were sequenced in two phases. To increase power to detect associations 
with modifying variants in the CFTR locus, all available F508del homozygous 
individuals in the Johns Hopkins CF Twin and Sibling Study (TSS) and the Genetic 
Modifier Study (GMS) with extremes of sweat chloride levels (Figure 3.1A) were 
selected for analysis.  A 210kb region encompassing CFTR and extending 10kb 5’ and 
5kb 3’ of the gene was sequenced in 583 subjects (486 F508del homozygotes and 97 
heterozygotes: Table 3.1).  Advances in capture technology following completion of the 
first phase enabled us to expand coverage of the CFTR locus in a second phase.  
Consequently, in phase 2, a 305 kb region fully encompassing the topologically 
associated domain (TAD) of CFTR (147, 148) plus an additional 300kb flanking this 
TAD was sequenced in 342 subjects (276 F508del homozygotes and 66 heterozygotes). 
The expanded region includes the neighboring genes WNT2, ASZ1, and CTTNBP2.  In the 
second phase, we selected the F508del homozygotes in the TSS from the extremes of 
lung function (Figure 3.1B).  By combining the two phases, we obtained F508del 
homozygous individuals drawn from the entire phenotype spectrum for sweat chloride 
function and lung function (Figure 3.2).  The F508del heterozygous samples were used 
only to inform haplotype studies.  Otherwise, the following results are specific to the 




A total of 652 variants (both SNPs and INDELs) were observed within CFTR in 
the F508del homozygous subjects.  Twenty four variants were observed within CFTR 
exons (n=13) (Tables 3.1, 3.2) or in the 5’ and 3’ UTRs (n=11) while the remaining 628 
were intronic. Two of the 13 exonic variants had MAF > 1%, (p.I1027T and p.Q1463Q), 
while a third variant, L467F (rs1800089), was detected at a frequency of 0.3% in CFTR 
genes bearing F508del. Of note from a clinical diagnostic perspective, L467F has been 
reported in individuals also carrying 1 copy of F508del diagnosed with CF related 
metabolic disorder (149-152).  Our results indicate that L467F is in cis with the F508del 
allele, indicating that it is not the trans CF variant leading to disease in these patients.  
However, due to low frequency in this population, we were not able to resolve the 
revertant potential of L467F or three other variants that cause an amino acid substitution 
(p.Q1330Q, p.R1438Y and p.V1475M) or five synonymous variants (p.L130L, p.I203I, 
p.T854T, p.I1404I and p.Q1463Q). None of these variants was predicted to activate 
cryptic RNA splicing (M. Lee, novel splice prediction algorithm, manuscript in 
preparation). Functional testing will be required to assess whether the amino acid 
substitutions affect the function of CFTR bearing F508del. Of note, the p.V1475M allele 
detected here was present in one of the original CFTR cDNAs that was widely 
distributed, and it appears to have no functional effect (153).  Finally, five variants 
initially mapped to the CFTR gene were discovered to be variants in regions of high 
homology to CFTR’s exon 10 (154, 155) (Table 3.3).  Together, these results indicate 





Single variant association analysis reveals no significant association with sweat chloride 
concentration or lung function 
Common variants with MAF > 1% (602 total variants; 235 in phase 1; 598 in 
phase 2) were assayed for association with either sweat chloride levels (Table 3.4) or 
lung function as measured by the age and survival adjusted phenotype SAKNORM 
(Table 3.5).  Linear regressions between number of minor alleles and the phenotypes 
were conducted on the Phase 1 and Phase 2 study samples separately and, for regions 
sequenced in both captures (the 210kb encompassing CFTR), in combination. All P-
values were calculated by permutation because of possibly non-normally distributed 
phenotypes (Supp Fig. 1C). 43 variants showed some evidence of association with point-
wise permutation p-values (p<.05) and 15 variants had beta values in the same direction 
when observed in both phase 1 and phase 2 cohorts (Tables 3.4 and 3.5).  None of these 
variants was statistically significant after multiple test correction using either max(T) 
permutation  (Supp Table 3) or by Bonferroni correction (not shown).  
One coding variant (p. I1027T) showed weak evidence of association with lung 
function (uncorrected point-wise permutation P=.0130).  Recognizing the limited power 
to detect associations of single rare variants with our traits (57% and 18% power at MAF 
.01 and an effect size of 1SD for sweat chloride and lung function respectively), we 
tested I1027T for association in a second, unrelated group of 748 F508del homozygotes.  
However, the association of I1027T with lung function did not replicate (P=0.8239). 
These results indicate no single common variant in cis with F508del was associated with 




Clusters of variants 5’ of and within CFTR correlate with sweat chloride concentration 
and lung function in F508del homozygotes  
A region-based burden assay was performed to identify groupings of variants 
which display associated with trait variation. Variants were tested for association with 
sweat chloride or lung function in groups defined by a series of overlapping 5kb windows 
(offset in 1250bp increments) with each window generating a test P-value. The P-value 
for each window was Bonferroni corrected for multiple testing based on the total number 
of unique windows assayed (see Methods). Regions of significance (hg19 coordinates, 
study-wide P<0.01) were highlighted for the combined test of common and rare variants 
associating with either sweat chloride concentration (Figure 3.3) and/or lung function 
(Figure 3.4).  Regions that coincided with known regulatory and boundary elements are 
discussed below (Table 3.6) (148, 156, 157). 
  A regulatory locus at -80kb is associated with both sweat chloride levels and lung 
function 
Variation in a locus denoted ‘Region A’ was associated with both sweat chloride 
concentration (study-wide corrected P=5.9e-4; region of statistical significance: 
chr7:117,039,250-117,053,000, Figure 3.3) and with lung function (study-wide corrected 
P=8.9e-3; chr7:117,030,500-117,050,000, Figure 3.4).  Region A is located 
approximately 80 kb 5’ of the CFTR transcription start site and within intron 4 of ASZ1. 
Chromatin conformation capture assays have shown that this region interacts with 
sequences in the CFTR promotor (148, 156). It also contains CTCF binding sites (Figure 




start site (148, 157, 158).  A total of 12 common and 9 rare variants are observed under 
the sweat chloride peak (Table 3.7). Of note are two variations in the length of a poly A 
tract, which may both be associated with higher sweat chloride concentration 
(7:117047463:TA>T and 7:117047463:TAA>T.  A total of 13 common and 3 rare 
variants are observed under the lung function peak (Table 3.8).  One of these variants 
(rs4730780, 7:117041448:T:A) that results in a decrease in length of a poly T tract, and 
an increase in length of the adjacent poly A tract, is located ~100bp from a known CTCF 
binding site(159).  The 4 individuals with this variant all had above average lung function 
(beta = +0.81 SAKNORM).     
Three Loci Associated with Sweat Chloride Levels 
Variation in 3 regions associated with sweat chloride concentration (Figure 3.3). 
Region B (chr7:116,941,750-116,951,750, P=7.1e-3, phase 2 coverage only, n=276) is 
located within intron 3 of WNT2 and contains 21 common and 9 rare variants (Table 
3.7).  This region lies outside CFTR’s topologically associated domain (TAD), and is 
adjacent to known CTCF binding sites in MCF7 and K562 cells (Figure 3.3).   Three 
individuals harbored what appears to be a haplotype of 4 rare variants (116942115:G>A, 
116942433:G>T, 116943135:C>T, 116944283:T>A, 3/552 chromosomes) and had lower 
mean sweat chloride concentration (~17mM Cl-).  These variants lie within or near a 
region of open chromatin and CEBPB binding site in fetal lung fibroblasts cells (IMR90 ) 
(159).  A common variant in the same region also showed evidence of association 
(P=0.02 uncorrected) with decreased sweat chloride levels (7:116943793:A>T, -8.63 mM 
Cl-).  Region C (chr7:117074250-117078000, P=3.3e-3, phase 1 and phase 2 coverage, 




CFTR(148). The variant with the most significant uncorrected p-value (117076029:G>A, 
P=0.001648, Table 3.7) lies within MTA3 and PML binding regions in GM12878 cells 
(160).  The final region significantly enriched for variants associating with sweat chloride 
levels (Region D, chr7:117153000-117156750, P=5.8e-3, phase 1 and phase 2 coverage, 
n=762) is located within intron 3 of CFTR, and contains 2 common and 7 rare variants.  
Region D contains no known functional elements and has various repetitive sequences.   
Two Distinct Loci Associated with Lung Function 
Variation in 2 regions associated with SAKNORM (Figure 3.4). Region E 
(chr7:117,010,500-117,014,250, P=.0058, phase 2 coverage only, n=276, intron 10 ASZ1) 
lies just outside of the proposed TAD containing CFTR (Figure 3.4), and contains 6 
common and 1 rare variants (Table 3.8).  Most of the variants are 2-4kb 3’ of known 
CTCF binding sites, but may influence interactions with regions outside of the CFTR 
TAD. Region F (chr7:117159250-117164250, P=3.3e-3, n=762) is located within intron 
3 of CFTR, slightly 3’ to region B associated with sweat chloride (Figure 3.3).  
Association here appears primarily due to common variation, specifically variations 
within a poly T tract (7: 117160319, 17T, 18T, or 16T).  Increasing the length of this tract 
is marginally associated with improved lung function (uncorrected P=0.0036), and 
conversely, decreasing the length of this tract is associated with poorer lung function 
(uncorrected P=0.0033) (Tables 3.4, 3.5, and 3.8).  The region has a large number of 
repetitive elements and no known functional elements.  





In addition to association testing, we also sought to systematically determine the 
genetic architecture at this locus in the F508del homozygous population.  Haplotypes are 
combinations of variants that tend to be inherited together (in cis).  Their borders are 
often delineated by recombination events which occur during meiosis.  Derivation of 
haplotypes are useful for establishing the degree of genetic diversity in a locus, 
associating functional variants with background variation and inferring ancestral origins 
of disease-causing variants. To assemble haplotypes, single nucleotide variants with 
MAF > 1% within the 510 kb region surrounding CFTR were phased using SHAPEIT2 
(161).  Samples bearing non-F508del chromosomes were used to deduce locations of 
alternative recombination events and additional diversity of the CFTR locus.  Linkage 
disequilibrium (LD) among variants with MAF > 2% in 762 F508del homozygotes 
revealed three primary regions of high LD, two of which encompassed CFTR (Figure 
3.5).  A recombination event was observed within intron 15 of CFTR, resulting in an 
alternative haplotype in LD block 2.  This recombination event is not present in 206 non-
F508del chromosomes which were sequenced using the same capture design.  The intron 
15 recombination event in F508del homozygotes is unique to this population, and is not 
apparent in HapMap populations (which contain a diversity of CFTR haplotypes only 
~5% of which is the F508del ancestral haplotype), where a distinct recombination event 
within intron 22 is observed (162).   
Using common variants with a MAF > 1%, we found that 16 haplotypes occurred 
at a frequency of 0.5% or higher in LD block 1 (CFTR exons 1-15) on chromosomes 
bearing F508del (Figure 3.6, Table 3.9).  The second LD block encompasses exons 16-




homozygous cohort.  Additional diversity is seen via inclusion of INDELs, but due to the 
large number of such sites observed in this region and their poly-allelic state, they were 
not included in the analysis presented.    
LD block 1 of CFTR encompassing the F508del allele displays primarily rare variation 
Limited common variation would be expected in the region of high linkage 
disequilibrium surround the F508del variant if it were inherited from a common founder 
ancestor of European descent (127).  Indeed, the autozygosity of this region is confirmed 
by the dearth of common variants in this haplotype (2/17 SNPs with MAF > 5%).  The 
majority of variation within this locus is very low frequency (15/17 SNPs with MAF 
between 1-5%).  Overall, ~70% of F508del homozygotes carry the same ancestral 
haplotype in LD block 1, with minor variations of this haplotype occurring in another 
30% of samples (Figure 3.6).  The majority of haplotypes in LD block 2 deviate from the 
ancestral haplotype by only one marker. One such haplotype contains I1027T 
(rs1800112), a variant known to be observed in cis with F508del (163). Our data, as well 
as data from the CFTR2 database (K. Raraigh and P. Sosnay, personal correspondence), 
indicate this allele and its associated haplotype are present on ~2.5% of F508del 
chromosomes (Figure 3.6, variant #1239, red asterisk).   
LD block 2 of CFTR contains two distinct haplotypes 
Due to the historical recombination event in intron 15 which occurred on an 
F508del-containing chromosome, a second distinct haplotype is observed in LD block 2 
that represents 1.9% of F508del chromosomes (Figure 3.6, bottom right).  The 




marker (rs138427389) (Figure 3.6, variant #1305).  Of note, this alternative haplotype 
contains the synonymous variant Q1463Q (rs1800136) (Figure 3.6, variant #1507).  
When samples bearing this alternative haplotype are removed from the F508del 
homozygous population, the recombination event within intron 15 is not observed 
(Figure 3.7). The majority of variation observed in LD block 2 is rare (46/47 SNPs with 
MAF between 1-5%). Overall, 85% of F508del chromosomes carry the ancestral 
haplotype in LD block 2, with the alternative haplotype as well as minor variations 
representing another 15% of chromosomes.  Finally, when considering only SNPs with 
MAF > 1% within the CFTR locus, ~55% of F508del chromosomes are completely 
identical across both regions of LD. 
 Thirteen single nucleotide variants capture all common (>1% frequency) haplotypes 
found on CFTR chromosomes bearing F508del 
By definition, haplotypes of a given LD block contain SNPs in high linkage 
disequilibrium.  As such, these haplotypes can be simplified by tagging variants.   In this 
process, all variants above a particular LD threshold are grouped and represented by a 
single variant, or ‘tag’.  
All haplotypes composed of SNPs with a MAF > 1% within the ~200kb 
surrounding CFTR are detailed in supplemental table 7, where a subset of 31 tagged 
SNPs (Table 3.10) captured 99.2% of the total ‘common’ variation at an r
2
 correlation 
value greater than 0.9.  Of these tagged SNPs, 13 were capable of representing all 




Haplotype-based studies using 13 tagged SNPs did not reveal any significant association 
with either sweat chloride concentration or lung function (data not shown).  
Mapping of Restriction Fragment Length Polymorphisms at the CFTR Locus 
CFTR was originally mapped using restriction fragment length polymorphisms 
(RFLPs) (32, 164). We mapped 8 of these RFLPs to within 2kb of their hg19 genomic 
coordinates, and have determined the coordinate and rsID of an additional 3 RFLPs 
(Figure 3.8).  These RFLPs primarily lie within LD block 1 (Intron 3 WNT2 to Intron 15 
CFTR), which includes the F508del allele.  Even RFLPs lying beyond this linkage block 
show residual LD with the F508del allele.  An example of this is H2.3A (XV-2C, 
rs3779549), which lies just beyond the recombination event in WNT2, but displays 
residual LD with the F508del locus.  This allele likely was on the same haplotype as 
F508del, but over time, recombination events decreased LD between these two markers.  
For this reason, the reference allele of H2.3A is enriched in the F508del population.  As 
the majority of CF patients carry at least one copy of the F508del allele, the high LD of 
these markers with this variant facilitated the localization of CFTR (34).  
Discussion 
We have systematically characterized both common and rare variation within and 
surrounding the CFTR locus in a large cohort of F508del homozygotes. Our initial goal 
was to determine if a coding region variant might moderate the deleterious effect of the 
F508del allele. A small number of rare exonic variants were observed in cis with 
F508del.  We found that neither a single common variant nor a combination of variants 




were unable to exclude four rare amino acid substitutions (p.L467F, p.Q1330E, 
p.R1438Y, and p.V1475M) as these variants were not frequent enough to allow for 
statistically valid association testing in this population.  Functional studies will be 
required to assess if these rare variants have any effect on CFTR bearing the F508del 
allele.  By extending analysis to non-coding sequences, we identified clusters of variants 
associating with variation in sweat chloride levels and/or lung function in proximity to 
regulatory elements 5’ of CFTR.  Using the rich dataset produced by sequencing the 
entire CFTR locus, we were able to resolve the genetic architecture surrounding the 
common CF-causing variant to an unprecedented level of detail. Haplotype analysis 
revealed that a single recombination event in intron 15 occurred in CFTR bearing the 
F508del variant. This event generated two regions of high linkage disequilibrium (LD) 
encompassing the CFTR locus. The LD block containing F508del extends into the WNT2 
gene, thereby facilitating the mapping of the CFTR locus. The dearth of common 
variation on haplotypes bearing the F508del variant is consistent with its single ancestral 
origin (163).  Finally, we were able to extract 13 haplotype-tagging SNPs that represent 
the vast majority of the genetic variation surrounding F508del.  The SNPs could be used 
to parse F508del homozygotes into sub-populations to test whether variation at the CFTR 
locus underlies differences in responses to molecular-targeted treatments.  
Basal transcription of CFTR is primarily driven by binding of factors at the 5’ 
promotor element (165).  However, recent studies have shown that additional cis 
regulatory elements are required for tissue specificity, abundance, and temporal 
expression (166, 167).  These cis regulatory elements have been shown to interact with 




CTCF binding (168).  Multiple chromatin interaction studies have now shown that these 
regulatory loci are encompassed within a topologically associated domain or TAD (148, 
157, 169), which is defined by boundary elements at -80kb and +49kb from CFTR.   
While much progress has been made regarding the chromatin structure in this region, 
resolving the function of each of these regulatory elements continues to be an active area 
of research.  
The results presented here posit that a burden of both rare and common variants at 
key loci may modulate the CF phenotype by alteration in the level and/or timing of 
expression of CFTR bearing F508del. These findings may inform future functional 
studies of the cis-regulatory elements identified in chromatin studies. The shared burden 
of rare and common variants associating with both CF traits at the -80kb regulatory motif 
is possibly the most striking finding we report.  We hypothesize that variants here may 
affect CTCF binding, or increase inherent enhancer activity.  This could lead to altered 
expression of the F508del transcript, which has some residual processing and function 
(96, 170-174). Presence of even small amounts of partially functional CFTR over the 
lifetime of an individual might be sufficient to moderate CF traits such as sweat chloride 
concentration and lung function (171).  The concept that natural variation in the 
expression level of mutated genes may underlie differences in the severity of inherited 
diseases is supported by recent studies of loss-of function yeast phenotypes (Vu et al Cell 
2016). Additionally, we posit that the intragenic and extragenic variation present in the 
F508del population may confer increased or decreased response to Orkambi™ or future 




The most 5' regions of interest (Regions B and E, Figures 3.3 and 3.4) were 
located within introns of WNT2 and ASZ1.  The region in WNT2 is located in an adjacent 
TAD to CFTR.  In a recent study, there was no report of this region interacting with the 
CFTR locus (157).  However, previous studies in epididymis cells indicate there are weak 
long range chromatin interactions with this region that may be cell type specific(148). It 
is possible that some of the rare variants associating with sweat chloride in the region are 
somehow modifying overall chromatin organization in certain cell types, such as the 
sweat gland.  Another distant region of interest was found within ASZ1, and is located 
just outside of the proposed CFTR TAD(157).  These regions are often enriched for 
TAD-TAD interactions, also known as inter-TAD interactions.  Variants here could alter 
CTCF binding, TAD architecture, or inter-TAD interactions.  Assaying both of these 
possible inter-TAD interactions could lead to additional insight into distant regulatory 
elements in ASZ1 and WNT2. Of note, the 5’ TAD boundary proposed by Smith and 
Dekker (2016) closely follows the recombination event in intron 10 of ASZ1 in this study, 
suggesting a possible link between recombinant events and chromatin structure in this 
region. 
Interestingly, adjacent regions within intron 3 of CFTR were found to associate 
with both sweat chloride levels and lung function (albeit, there is no distinct overlap 
given the coordinates identified here). To our knowledge, this region has not previously 
been shown to have regulatory function.  While the intron 3 signal for sweat chloride was 
primarily composed of rare variation, common variation in the length of a poly T tract 
resulted in the lung function association.  Interestingly, while not significant, the 18T and 




3.58 mM Cl- and P=.08, beta=+3.49 mM Cl- respectively).  Given the lack of functional 
elements and low conservation in this region, it is currently challenging to imagine a 
mechanism by which this alteration could modulate CF traits. However, poly T tracts 
may regulate gene expression by acting as matrix attachment regions (MARs) (175), or 
may participate in RNA triplex formation (176). We do note that this poly T tract still 
may modulate lung function when the cohorts are considered independently (18T allele: 
P=.051, beta=+0.18, n=486 and P=0.12, beta=+0.19, n=276).   
A recurring theme through-out the variation observed in this study was variable 
lengths of repetitive elements associating with disease severity.  These INDELs may 
represent a mode of phenotype modification that is not well characterized (177), but has 
been previously observed to modify the phenotype of other CF-causing alleles (i.e. 
R117H and polyT tract) (144). This type of variation is observed in 5 of the 7 regions of 
interest.  We recognize that this form of variation can be difficult to accurately call using 
next generation sequencing methods.  However, all INDELs reported here were of both 
high mapping and variant call qualities, and exhibited Hardy Weinberg equilibrium. It is 
possible that these small variants may be partially marking larger repetitive sequences 
that could not be typed in this study due to read length (or high homology).  Additional 
studies of common and rare INDELs at these loci could reveal a mechanism of phenotype 
modification.  Finally, we recognize that some of the assays employed here have limited 
power, especially at low minor allele frequencies given the cohort size (which ranges 
from 276 to 762, depending on the region assayed). Power is additionally limited when 
assaying sweat chloride associations in the phase 2 cohort, as this cohort was selected for 




these limitations, the study presented here likely contains false negatives, which could 
only be resolved using larger cohorts. 
Some sequencing studies fail to consider regions of known homology with the 
region of interest.  In this study, we opted to allow for a higher frequency of false 
positives in regions of the capture with high homology to pseudogenes (specifically 
intron 9 and exon 10 of CFTR, Table 3.3) (155).  This was to allow for more consistent 
tiling of baits, better detection of large structural variants, and a more complete capture 
overall.  Clinical labs should be aware of these regions when designing assays in order to 
minimize erroneous calls.  For example, the nonsynonymous mutation A455E is a high 
frequency CF-causing allele in exon 10.  This variant is also present in a pseudogene 
present on chromosome 20.  While this variant can be correctly typed using a longer read 
length, short amplifications cannot distinguish between these two forms (178).  The 
variants reported in Table 3.3 could be assigned to either the chromosome 9 or 
chromosome 20 pseudogenes due to their reoccurrence in a small subset of samples 
(n=5); however, alternative methods would be required in a clinical setting.  
Overall variation was rare within the LD block containing F508del, consistent 
with a single ancestral origin of this allele in the population.  When considering only 
common SNPs (MAF>1%), the majority of F508del chromosomes (~55%) are 
completely identical. These results indicate the F508del homozygous population is highly 
homogenous, with the majority of variation being private or due to a low-frequency 
recombination event within intron 15. Because this event is not observed on non-F508del 
chromosomes, it likely occurred after F508del arose.  Previously, a recombination event 




was based on population level data provided by the HapMap project, which used wild-
type CFTR and had significantly reduced marker density compared to this study (179).  
Newer HapMap releases suggest two possible primary recombination events in the 
general population: intron 11 and intron 15-intron 16.  The intron 15-intron 16 event 
likely represents F508del carriers, as it is primarily observed in European populations. 
The previously reported intron 22 event may have some limited evidence in Mexican and 
Italian Hapmap cohorts.  
We have now made available a detailed map of common variation and population 
based haplotypes for the F508del locus (Table 3.9). In summary, this study has 
methodically characterized variation in cis with the F508del allele and the genetic 
architecture of this locus in great depth. Collectively, our findings suggest a combination 
of rare and common variation within suspect and known regulatory regions at the CFTR 
locus may contribute to the phenotypic heterogeneity observed in F508del homozygous 
CF patients.  The identified variation may modify CFTR expression levels and/or timing 












To increase the power to detect associations with CF traits, patient samples were 
selected at the extremes of phenotypes (180).  These extremes were defined by plotting a 
normal distribution of these traits in F508del homozygotes which are part of the Johns 
Hopkins Twin and Sibling Study (TSS) (181) (Figure 3.1).  Samples selected for the 
phase 1 of this study had sweat chloride levels +/- 1SD from the population mean, and 
were recruited from either the TSS or the University of North Carolina’s Genetic 
Modifiers Study (GMS).  Of note, the distribution of sweat chloride in the GMS was 
highly similar to that of the TSS. In phase 2 of the study, samples were similarly selected 
from extremes of SAKNORM, an age and mortality adjusted CF-population specific 
measure of lung function (182), and were recruited from the TSS.  
Sample consent and DNA preparations: 
Patients in this study were recruited to either the Johns Hopkins Twin and Sibling 
Study(181) (TSS) or the University of North Carolina’s Genetic Modifiers Study (183) 
(GMS).  Peripheral blood was previously obtained from all consented individuals as part 
of their respective studies, and genomic DNA was extracted by a phenol-chloroform 
protocol. Phenotype information for TSS and GMS cohorts was collected as part of their 
respective studies, and was taken from both study admission forms, as well as the Cystic 
Fibrosis Foundation's Annualized Database.  




Capture design and sequencing was conducted at the Center for Inherited Disease 
Research (CIDR), which implemented a 3-tiered process to design the reagent.  The first 
pass includes 1x tiling density with ‘most stringent’ masking of repetitive regions, and 
maximum performance boosting for probe re-balancing which replicates any GC rich 
probes based on Agilent’s exome capture algorithm to improve uniformity.  Regions not 
covered from the first pass were re-submitted with relaxed parameters (1x tiling, 
moderate stringency masking and balanced boosting) in an attempt to provide complete 
coverage across the regions of interest.  Any regions not covered from this second pass 
were re-submitted using a lower stringency (1x tiling, least stringency masking and no 
boosting).  All probes obtained at each pass were analyzed using BLAT, allowing 
determination of probe uniqueness, which aided in estimating impact on percent selection 
and mapping quality. Any probe which had a BLAT score of <40 was flagged, and 
flagged probes were reviewed with the authors for further evaluation. 
Library Prep, Capture, and Sequencing: 
1ug of genomic DNA was sheared using the Covaris E210 instrument (Covaris), 
shear time was decreased to 80 seconds in order to obtain larger insert sizes.  A hybrid 
protocol for library preparation and whole exome enrichment was developed at 
CIDR(unpublished) based on methods and parameters from Fisher, applied to the 
reagents, volumes and parameters from the Agilent SureSelect XT kit and automated 
protocol (p/n G7550-90000 revision B).  All processing was done in 96 well plate 
formats using robotics (Beckman F/X, Perkin-Elmer Multiprobe II, Agilent Bravo, 
Beckman Biomek 2000).  ‘With Bead’ clean ups were used following shearing, end 




Coulter Genomics) beads was based on volumes from the Agilent protocol.  After the 
first clean up the sample was eluted and the beads remained in the reactions through the 
final ligation clean-up.  These reactions were carried out using the XT reagent kits, 
volumes and conditions described in the Agilent protocol.  At pre-capture PCR the entire 
product was amplified, adjusting the water in the reaction to accommodate the increase in 
DNA sample volume. The PCR enzyme used in all steps was switched from Herculase to 
Kapa Biosystems HiFi HotStart Ready Mix.  The Kapa enzyme increases coverage in GC 
rich regions.  All other aspects follow the Agilent protocol except the number of PCR 
cycles was increased from 6-8 cycles.  750ng of amplified library was used in an 
enrichment reaction following Agilent protocols (24 hour hybridization).  Post-capture 
washing was done using the Agilent protocol except the  ‘off-bead’ catch process from 
Fisher et al., was incorporated (samples are not eluted off the DynaBeads (Invitrogen), 
instead post-capture PCR master mix and indexes are added directly to the beads).  Post-
capture PCR was done according to the Agilent protocol, with the adjustment of water 
volume and PCR cycles where needed.  For low input samples, 50ng of genomic DNA 
was sheared using the Covaris E210 instrument (Covaris), using the same parameters as 
the 1ug input samples.  Library prep was performed using the Kapa Hyper Prep kit (Kapa 
Biosystems) according to the manufacturer’s protocol.  Indexed adapters, primers and 
blockers used in the low input protocol were custom synthesized by Integrated DNA 
Technologies and were used in accordance to the Kapa protocol specifications.  The 
hybridization for capture was set up according to the Agilent XT protocol with the 




capture washing was done using the Agilent protocol except the  ‘off-bead’ catch process 
from Fisher et al., was incorporated (samples are not eluted off the DynaBeads 
(Invitrogen), instead post-capture PCR master mix are added directly to the beads).  Post-
capture PCR was done according to the same parameters used for the pre-capture PCR 
adjusting for PCR cycles. DNA sequencing was performed on an Illumina® HiSeq 2500 
instrument using standard protocols for a 100 bp paired-end run.  96 samples were run 
per flowcell, guaranteeing >90% completeness at a minimum of 20X coverage. Intensity 
analysis and base calling were performed through the Illumina Real Time Analysis 
(RTA) software (version 1.17.20).  Basecall files were converted from a binary format 
(BCL) to flat file format (qseq.txt) using the Illumina BCL Converter software (version 
1.9.4).  qseq.txt files were demultiplexed to single sample fastq files using a 
demultiplexer written at CIDR as part of CIDRSeqSuite version 3.2. 
Variant Calling and Annotation: 
Briefly, reads were first aligned to the genome using Burrows-Wheeler Aligner 
Mem algorithm (115) (v.0.7.8), duplicate reads were marked using PicardTools (v.1.109), 
realignment around INDELs and base quality score recalibration were  performed via the 
Genome Analysis Tool Kit (v.3.1-1)(83).  Small variant calling was conducted using 
three software: GATK’s assembly based haplotype callers, FreeBayes, and Platypus.  The 
final call-set required that a variant or INDEL be called by at least two algorithms 
(custom scripts allowed adjustment of INDEL call positions).  In GATK, per sample 
gVCFs were used for joint calling of the entire cohort.  The call-set was further refined 
by hard filters (VQSR not applicable in this targeted dataset).  Variant filters generally 




quality >=40.  Alternative and additional filters were applied to INDELs. Large structural 
variants were called via Conifer and Breakdancer software. Custom scripts then 
annotated the call set for disease causing CFTR variants as defined by CFTR2, and typed 
known repeats of interest (poly T and TG tracts).   
Data Cleaning: 
The CFTR genotype of each of the samples in this cohort was checked for 
concordance to study admission records.  Of the 790 F508del homozygotes sent for 
sequencing, 15 were found to carry alternative genotypes (i.e. G551D, I507del, etc).  
These samples were removed from the F508del cohort.  Given that nearly all samples 
sequenced had SNP level genotypes available from a previous genome wide association 
study (GWAS), concordance was checked between the 82 typed SNPs in our targeted 
regions and the GWAS call set.  The overall concordance rate was 99.2%.  Discordant 
samples (likely plated erroneously in either study) were removed from the analysis.  One 
sample was found to have Klinefelter syndrome (SNP data consistent with a karyotype of 
47,XXY and verified via clinical contact), and was removed from the analysis.  Two 
samples were found to contain large structural deletions and were removed from the 
analysis. Identity by state analysis was used to predict unknown related samples. 
Population stratification was assayed via principle component analysis.  No significant 
stratification was observed beyond the second ancestral haplotype in LD block 2 of 
CFTR (principle component 1). This stratification did not correlate with either reported 
ancestry or known HapMap populations.  The entire cohort most closely resembles TSI 
and CEU HapMap populations.  The above analyses were conducted using combinations 




Common Variant Association Testing: 
Variants with MAF > 1% in the F508del homozygous population were assayed 
for association with either sweat chloride levels or SAKNORM using linear regression 
analysis in the Plink software package v1.9(184).  Data was initially cleaned for 
individual and SNP missingness, and IBD structure (to remove a select few related 
samples). Empiric point-wise and study-wide corrected P-values were calculated using 
Max(T) permutation testing (PLINK --mperm command with 1x10
6
 permutations).  
Common and Rare Variant Burden Testing: 
The optimized sequence kernel association test (SKAT-O) was used in this study 
as it maintains power when a large portion of variants are neutral or have opposing 
direction of effects (185) (power for 762 subjects is ~70% in regions where 20% of the 
variation is non-neutral). To increase power for this test, the combined cohorts were used 
to test association in regions of overlapping coverage (Figure 1, bottom track).  Common 
and rare variants were grouped according to a MAF cut-off of 1% in the F508del 
homozygous population.  A 5kb sliding window was then moved across the entire capture 
region in 1250bp increments.  Common and rare variants falling within these regions 
were grouped for region based burden testing using the SKAT-O algorithm, implemented 
in R.  Variants were assayed for either common, rare, or combined burden testing using 
the “SSD” commands which allow for loading of a plink formatted dataset. The method 
employed in all cases was “optimal.adj”, representing the optimized method.  The 
resulting region based burden p-values were tested for study-wide significance by 




which contained the same set of variants as another window were not counted as 
independent tests.  In the 510kb captured region encompassing the CFTR locus and 
surrounding genes, a total of 404 windows were present.  Of these 320, 186, and 374 
were independent tests for rare, common, and combined tests, respectively. All SKAT-O 
derived p-values were corrected for the above mentioned multiple testing. Statistical 
significance was defined as a P-value less than 0.01 after correction for the number of 
windows used in the analysis. 
Phasing and Haplotype Analysis: 
Variants in the F508del homozygous population (n=762) with MAF > 1% were 
phased using phase informative reads in SHAPEIT2, with recommended settings.  LD 
blocks and haplotypes were confirmed and visualized using Haploview.  To convey 
relevant information from supplemental Figure 1 in a non-matrix format, a custom perl 
script was used to calculate the ratio of r
2
 correlation values on either side of a given 
variant.  Plink v1.9 was first used to generate r
2
 values for up to 20 possible variant pairs 
within 10kb of a given SNP (--r
2
 --ld-window 20 –ld-window-kb 10 –ld-window-r
2
 0). 
These values were entered into a script which divided these pairings into variants either 
upstream or downstream of the locus in question. The recombination ratio was then 
calculated as: [mean r
2
 of the SNP with upstream variants / mean r
2
 of the SNP with 
downstream variants].  The recombination ratio by distance was then plotted using R.   
Haplotype Based Association Testing: 
CFTR haplotypes as defined by tagged variants in Supplemental Table 6 were 




homozygous cohort.  This analysis was conducted in Plink v.1.07 using the --chap and --
each-vs-others commands.  Only haplotypes with frequencies > 1% were assayed. 
Power Calculations: 
Study phase specific power calculations were conducted using custom R scripts 
adapted from Guey and Voight 2011 (186).  Key parameters include the sample size 
(n=486 for phase 1, n=276 for phase 2), extremity of phenotypes (+/- 1 SD), and the 
percentage of phenotypic variance attributable to mutations within the CFTR locus (50% 










Figure 3.1. Selection of individuals from extremes of distribution of sweat chloride 
concentration or lung function. 
A) Density plot of sweat chloride levels in F508del homozygotes in the Johns Hopkins 
Twin and Sibling Study (TSS; n =784). Dotted lines indicate thresholds used for selecting 
samples for phase 1 of this study at either -1 or +1 SD (~15mM Cl-) from the mean 
(~101.5mM Cl-).  Using these thresholds, 231 samples were selected from TSS, and 255 
from Genetic Modifier Study (GMS) for phase 1.  B) Density plot of SAKNORM levels 
in F508del homozygotes in the Johns Hopkins Twin and Sibling Study (TSS; n=1205). 
Dotted lines indicate threshold for selecting samples for phase 2 of this study at either -1 
or +1 SD (0.8 SAKNORM units) from the mean (0.45 SAKNORM).  A total of 276 






Figure 3.2.  Distribution of sweat chloride concentration and lung function 
phenotypes by study phase.  Density plots are shown to indicate distribution of trait  








Table 3.1. Re-sequencing Summary Statistics and Variant Annotation. 
 
F508del # samples 762
Start/End of Phase 1 Capture chr7:117107678-117317732
Start/End of Phase 2 Capture chr7:116916359-117426330
Total Targeted Bases 191,621 (n=486, Original Phase 1 Capture Design) 
400,150 (n=276, Expanded Phase 2 Capture Design)
% Bases Depth > 20x 98.2% (n=486, Original Phase 1 Capture Design) 
97.6% (n=276, Expanded Phase 2 Capture Design)
Mean Depth of Coverage 176x (n=486, Original Phase 1 Capture Design) 
94x (n=276, Expanded Phase 2 Capture Design)
Ts/Tv Ratio 2.3 (n=762, Combined Captures) 
Total Variants 1,388
Common (MAF > 1%) 602
Rare (MAF < 1%) 786






+/- 20 bp of canonical splice 9
Intronic 628




Exonic, 5'/3' UTR 37
Intronic 465
Summary statistics are provided for the 510kb region surrounding the CFTR locus in 
F508del homozygous patients only. The project was completed in two phases, with 
separate, but semi-overlapping re-sequencing captures (see original vs expanded capture). 
All variant call statistics are provided for the combined capture. Intragenic variants have been 
divided into CFTR (blue highlight) and others (yellow highlight).  All genomic coordinates are 
from build hg19.










Table 3.3. Mis-mapped CFTR Exonic Variation Due to Extragenic Regions of High 





Table 3.4. Common Variant Sweat Chloride Level Associations. 
Variants above 1% minor allele frequency in F508del homozygotes associating with 
sweat chloride levels via linear regression prior to multiple test correction (uncorrected p-
value < .05, 21/602 total common variants).  Overall beta values correspond to the either 
the combined or phase 2 only associations and indicate increase or decrease in mM Cl- 
units.   Multiple test corrected combined study phase p-value is indicated by Max(T) 
permutation.  Other combined and phase-specific uncorrected p-values were empirically 





























116929105 CTT C INDEL
Intron 4 
WNT2 0.013 381 5 10.57 - 0.0174 - 0.992
116943793 A T SNP
Intron 3 
WNT2 0.016 380 6 -8.64 - 0.0309 - 1.000
116950636 C CAAA INDEL
Intron 3 
WNT2 0.088 353 31 4.74 - 0.0061 - 0.876
117002471 A AT INDEL
800bp 3' of 
ASZ1 0.060 364 22 5.33 - 0.0128 - 0.990
117019187 18 TA 7 TA INDEL
Intron 10 
ASZ1 0.008 383 3 -11.21 - 0.0466 - 1.000
117044471 CT C INDEL
Intron 4 
ASZ1 0.049 368 18 -4.96 - 0.0341 - 1.000
117047463 TA T INDEL
Intron 4 
ASZ1 0.940 199 187 8.26 - 0.0383 - 1.000
117065313 C CTTT INDEL
Intron 2 
ASZ1 0.108 31 287 4.01 - 0.0033 - 0.630
117085677 CT C INDEL
35kb 5' 
CFTR 0.253 78 308 2.84 - 0.0396 - 1.000
117106383 G A SNP
14kb 5' 
CFTR 0.011 380 4 -11.64 - 0.0201 - 0.995
117144829 G GAAA INDEL
Intron 2 
CFTR 0.019 375 7 -7.59 - 0.0371 0.0350 1.000
117153491 G GAA INDEL
Intron 3 
CFTR 0.072 1258 90 7.02 0.0091 0.1504 0.0096 0.977
117250479 CA C INDEL
Intron 18 
CFTR 0.640 822 526 -5.13 0.0214 0.6682 0.0202 1.000
117252108 C T SNP
Intron 20 
CFTR 0.022 894 20 12.83 0.0421 - 0.0421 1.000
117258532 TCA T INDEL
Intron 21 
CFTR 0.403 818 330 5.51 0.0042 0.1870 0.0029 0.673
117284114 C CT INDEL
Intron 23 
CFTR 0.016 380 6 -8.95 - 0.0256 0.0200 1.000
117302037 23 G 24 G INDEL
Intron 24 
CFTR 0.344 1003 345 5.40 0.0047 0.9382 0.0030 0.984
117302037 23 G 22 G INDEL
Intron 24 
CFTR 0.108 1217 131 -5.96 0.0131 0.5779 0.0106 0.699
117357046 T C SNP
Intron 22 
CTTNBP2 0.038 372 14 -5.31 - 0.0431 - 1.000
117403609 CTT C INDEL
Intron 9 
CTTNBP2 0.221 308 68 3.74 - 0.0025 - 0.597
117419783 CAT C INDEL
Intron 7 















Table 3.5. Common Variant Lung Function Associations. 
Variants above 1% minor allele frequency in F508del homozygotes associating with a 
change in lung function, as assessed by SAKNORM (22/602 total common variants).  































116933160 T TA INDEL
Intron 4 
WNT2 0.010 483 5 1.12 - 0.0067 - 0.924
116941856 CTT C INDEL
Intron 3 
WNT2 0.224 410 92 0.24 - 0.0270 - 1.000
116944486 ATTT A INDEL
Intron 3 
WNT2 0.056 462 26 -0.41 - 0.0332 - 1.000
117012943 A G SNP
Intron 10 
ASZ1 0.017 484 8 -0.69 - 0.0083 - 0.981
117033209 T TA INDEL
Intron 4 
ASZ1 0.056 462 26 -0.51 - 0.0076 - 0.949
117081552 21T 23T INDEL
14.5kb 5' 
ASZ1 0.038 470 18 0.52 - 0.0209 - 1.000
117081552 21T 19T INDEL
14kb 5' 
ASZ1 0.054 463 25 -0.41 - 0.0347 - 1.000
117106419 C CTT INDEL
13.5kb 5' 
CFTR 0.084 450 38 0.33 - 0.0408 - 1.000
117138870 G GTTTT INDEL
Intron 1 
CFTR 0.069 829 57 -0.28 0.0175 - 0.0176 0.999
117144829 G A SNP
Intron 2 
CFTR 0.111 1233 137 0.17 0.4222 0.0207 0.0366 1.000
117152687 CAA C INDEL
Intron 3 
CFTR 0.233 1114 260 -0.20 0.0781 0.0402 0.0041 0.810
117158623 CAT C INDEL
Intron 3 
CFTR 0.294 1045 307 -0.13 0.1869 0.0458 0.0435 1.000
117160319 17T 18T INDEL
Intron 3 
CFTR 0.472 931 439 0.20 0.0510 0.1169 0.0037 0.771
117160319 17T 16T INDEL
Intron 3 





CFTR 0.074 94 1270 0.21 0.0162 0.4595 0.0207 1.000
117206653 TA T INDEL
Intron 11 
CFTR 0.021 1346 28 -0.37 0.6681 0.0137 0.0287 1.000
117226828 CT C INDEL
Intron 11 
CFTR 0.078 1274 100 0.20 0.2810 0.0219 0.0313 1.000
117250664* T C (I1027T) SNP
Exon 19 
CFTR 0.032 1332 42 0.34 0.0364 0.2103 0.0130 0.995
117252077 G GTATA INDEL
Intron 20 
CFTR 0.225 976 220 0.13 0.1791 0.1412 0.0360 1.000
117278790 C CATAA INDEL
Intron 22 
CFTR 0.024 1293 31 -0.29 0.2221 0.0855 0.0435 1.000
Phase 2 
Coverage 
Only 117363806 CTTT C INDEL
Intron 19 












Table 3.6. Regions Found to Interact with CFTR Promotor via Chromatin Capture 
by either Dekker or Harris groups. 
   
 
Abbreviated Full Reference
Smith and Dekker 2016
Yang and Harris 2015
Chromosome Start (hg19) End (hg19) References Additional Annotation
chr7 117035669 117046178 Smith and Dekker 2016 / Yang and Harris 2015 -80kb
chr7 117046179 117050387 Smith and Dekker 2016
chr7 117050388 117057168 Smith and Dekker 2016
chr7 117057169 117062301 Smith and Dekker 2016
chr7 117075245 117076245 Smith and Dekker 2016 / Yang and Harris 2015 -44kb
chr7 117078458 117079183 Smith and Dekker 2016
chr7 117079184 117082828 Smith and Dekker 2016
chr7 117082829 117083304 Smith and Dekker 2016
chr7 117084910 117086709 Yang and Harris 2015 -35kb
chr7 117094392 117100244 Smith and Dekker 2016 / Yang and Harris 2015 -20.9kb
chr7 117120896 117125750 Smith and Dekker 2016
chr7 117129829 117130579 Yang and Harris 2015 exon1+10kb
chr7 117133646 117135039 Smith and Dekker 2016
chr7 117139373 117140740 Smith and Dekker 2016
chr7 117167209 117172399 Smith and Dekker 2016
chr7 117172400 117179549 Smith and Dekker 2016
chr7 117211555 117213631 Smith and Dekker 2016 / Yang and Harris 2015 intron11ab
chr7 117220582 117223082 Yang and Harris 2015 intron 11c
chr7 117224217 117229090 Smith and Dekker 2016 / Yang and Harris 2015 intron 12
chr7 117237162 117245849 Smith and Dekker 2016
chr7 117255414 117258789 Smith and Dekker 2016
chr7 117273186 117274601 Smith and Dekker 2016
chr7 117296108 117301295 Smith and Dekker 2016
chr7 117302414 117304652 Smith and Dekker 2016
chr7 117304653 117304780 Smith and Dekker 2016
chr7 117305161 117306850 Smith and Dekker 2016
chr7 117307580 117308782 Smith and Dekker 2016
chr7 117326535 117332210 Smith and Dekker 2016
chr7 117332211 117336769 Smith and Dekker 2016
chr7 117336770 117337958 Smith and Dekker 2016
chr7 117337959 117341506 Smith and Dekker 2016
chr7 117355221 117357250 Yang and Harris 2015 +48.9kb
Smith, E.M., Lajoie, B.R., Jain, G., and Dekker, J. (2016). Invariant TAD Boundaries Constrain Cell-Type-
Specific Looping Interactions between Promoters and Distal Elements around the CFTR Locus. Am J Hum 
Genet 98, 185-201.
Yang, R., Kerschner, J.L., Gosalia, N., Neems, D., Gorsic, L.K., Safi, A., Crawford, G.E., Kosak, S.T., Leir, 
S.H., and Harris, A. (2015). Differential contribution of cis-regulatory elements to higher order chromatin 




         
Figure 3.3. Burden Testing of Common and Rare Variants Associating with Sweat 
Cl- Levels. 
All variants within each 5kb window, moved across the entire region in increments of 
1250bp, were tested for a combined association with sweat chloride levels (mM) via 
SKAT-O test.  X-axis denotes chr7 hg19 bp position, y-axis is –log10 of the regional p-
value.  Association values were plotted at the center of each 5kb window. Top (Red):  




only.  Bottom (Purple): Combined test of common and rare variants with variants 
weighted inversely proportional to their frequency. Vertical shaded boxes: regions of 
significant association in the combined analysis (ɑ=.01). Genome browser style tracks:  
Top, packed view of known CFTR regulatory regions of interest as previously reported 
(see supplemental file).  Middle, view of genes with exonic/intronic structure.  Bottom, 
CTCF binding signals in two cell types, and mammalian conservation as assayed by 








Figure 3.4. Burden Testing of Common and Rare Variants Associating with Lung 
Function (SAKNORM). 
All variants within each 5kb window, moving across the entire region in increments of 
1250bp, were tested for a combined association with lung function (SAKNORM) via 
SKAT-O test.  X-axis denotes chr7 hg19 bp position, y-axis is –log10 of the regional p-
value.  Association values were plotted at the center of each 5kb window. Top (Red):  




only.  Bottom (Purple): Combined test of common and rare variants with variants 
weighted inversely proportional to their frequency.  Vertical shaded boxes: regions of 
significant association in the combined analysis (ɑ=.01).Genome browser style tracks:  
Top, packed view of known CFTR regions of interest as previously reported (see 
supplemental file).  Middle, view of genes with exonic/intronic structure.  Bottom: CTCF 
binding signals in two cell types, and mammalian conservation as assayed by GERP 






Table 3.7. Variants within regions associating with sweat chloride levels via SKAT. 
Region A
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (Mm Cl-) Uncorrected Variant P-value
7:117044382:C:CT 194 96 0.495 -2.522 0.06313
7:117044382:CT:C 258 64 0.248 1.068 0.4603
7:117044471:C:CTT 366 10 0.027 2.128 0.4888
7:117044471:CT:C 350 18 0.051 -4.962 0.03325
7:117045434:C:T 384 1 0.003 9.349 0.3242
7:117046808:C:CA 264 61 0.231 1.231 0.4008
7:117046808:CA:C 268 59 0.220 -1.027 0.4875
7:117047463:TA:T 12 187 0.064 8.264 0.03432
7:117047463:TAA:T 382 2 0.005 23.24 0.0004516
7:117048043:G:A 384 1 0.003 -12.26 0.1956
7:117048087:C:T 384 1 0.003 2.313 0.8076
7:117050389:T:TTA 384 1 0.003 2.313 0.8076
7:117050798:GA:G 382 2 0.005 16.47 0.01365
7:117052093:A:AGTGTGTAT 354 16 0.045 0.5097 0.8367
7:117052093:AGT:A 384 1 0.003 -19.3 0.041
7:117052094:G:GTGTGTA 2 192 0.010 4.724 0.6188
7:117052096:G:GTGTA 14 186 0.075 0.4438 0.9031
7:117052098:G:GTA 326 30 0.092 1.195 0.5252
7:117052100:G:A 370 6 0.016 2.153 0.585
7:117052102:G:A 384 1 0.003 -19.3 0.041
7:117052846:A:C 384 1 0.003 4.223 0.6565
Region B
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (Mm Cl-) Uncorrected Variant P-value
7:116941856:C:CT 338 24 0.071005917 -3.087 0.134
7:116941856:C:CT 380 3 0.007894737 -17.3 0.001467
7:116941856:C:CT 382 2 0.005235602 -3.233 0.631
7:116941856:C:CTT 340 27 0.079411765 0.6333 0.7087
7:116941856:C:CTTT 350 18 0.051428571 0.01316 0.9955
7:116941856:C:CTTTT 348 19 0.054597701 0.8883 0.6978
7:116941856:CT:C 242 72 0.297520661 -0.9596 0.4958
7:116941856:CTT:C 258 68 0.263565891 1.33 0.3105
7:116942115:G:A 380 3 0.007894737 -17.3 0.001467
7:116942433:G:T 380 3 0.007894737 -17.3 0.001467
7:116942912:G:A 372 7 0.018817204 -0.9478 0.7949
7:116943281:C:A 382 2 0.005235602 2.527 0.7073
7:116943793:A:T 374 6 0.016042781 -8.634 0.02696
7:116944283:T:A 380 3 0.007894737 -17.3 0.001467
7:116944481:T:C 378 4 0.010582011 5.26 0.271
7:116944484:A:C 360 12 0.033333333 -0.3475 0.9023
7:116944486:AT:A 162 62 0.382716049 0.01824 0.9922
7:116944486:ATT:A 148 119 0.804054054 -1.513 0.2797
7:116944486:ATTT:A 354 16 0.04519774 -0.2978 0.9041
7:116944486:ATTTTTTT:A 360 13 0.036111111 0.4875 0.8578
7:116945583:G:T 384 1 0.002604167 12.36 0.1919
7:116947196:A:C 366 10 0.027322404 -3.743 0.2227
7:116947789:C:A 384 1 0.002604167 -13.27 0.1613
7:116947844:A:T 362 12 0.033149171 -2.034 0.471
7:116948171:C:A 372 7 0.018817204 -5.617 0.1223
Region C
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (Mm Cl-) Uncorrected Variant P-value
7:117074330:A:G 384 1 0.003 11.36 0.2307
7:117074834:A:T 384 1 0.003 -8.242 0.385
7:117076029:G:A 382 2 0.005 -20.92 0.001648
7:117076523:G:A 384 1 0.003 -4.724 0.6188
7:117077757:A:T 384 1 0.003 13.37 0.1581
7:117078936:T:A 384 1 0.003 -11.76 0.2146
Region D
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (Mm Cl-) Uncorrected Variant P-value
7:117153275:A:G 960 1 0.001 -30.3 0.2741
7:117153491:G:GAA 1168 90 0.077 7.023 0.009601
7:117153491:GA:G 1330 9 0.007 -2.329 0.7725
7:117153761:A:AT 1338 5 0.004 27.87 0.009528
7:117154574:G:A 960 1 0.001 16.8 0.5446
7:117155052:G:GT 894 34 0.038 2.813 0.5681
7:117155422:A:G 944 3 0.003 13.48 0.3992
7:117155926:T:C 960 1 0.001 -30.3 0.2741





Table 3.8. Variants within regions associating with lung function via SKAT. 
 
Region A
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (SAKNORM) Uncorrected Variant P-value
7:117032902:C:CT 312 88 0.282 -0.000694 0.9955
7:117032902:CT:C 206 141 0.684 -0.02552 0.8314
7:117032902:CTT:C 468 10 0.021 -0.1418 0.6349
7:117033209:TA:T 246 121 0.492 0.1024 0.387
7:117033209:T:TA 436 26 0.060 -0.5075 0.007731
7:117036759:A:G 482 3 0.006 -1.097 0.04039
7:117041435:GT:G 220 134 0.609 0.01611 0.8923
7:117041435:GTT:G 406 41 0.101 0.1244 0.432
7:117041448:T:A 480 4 0.008 0.8106 0.08123
7:117043459:C:T 480 4 0.008 0.1836 0.6938
7:117044382:C:CT 236 126 0.534 -0.01676 0.8876
7:117044382:CT:C 326 81 0.248 0.4209 0.07924
7:117044471:C:CTT 462 13 0.028 -0.02575 0.9222
7:117044471:CT:C 440 24 0.055 0.008147 0.9673
7:117046808:CA:C 350 69 0.197 -0.05393 0.6817
7:117046808:C:CA 332 78 0.235 0.04221 0.7396
Region B
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (SAKNORM) Uncorrected Variant P-value
7:117010858:TTG:T 458 15 0.033 -0.4275 0.08197
7:117010858:TTGTG:T 482 3 0.006 -0.1513 0.7782
7:117010858:T:TTG 26 238 0.109 -0.05116 0.8053
7:117010858:T:TTGTG 426 31 0.073 -0.02861 0.8722
7:117010858:T:TTGTGTG 474 7 0.015 -0.3241 0.3605
7:117011094:G:A 468 10 0.021 0.1029 0.7304
7:117012943:A:G 476 8 0.017 -0.6888 0.01022
Region C
Variant # Chr Allele 1 # Chr Allele 2 Frequency Variant Beta (SAKNORM) Uncorrected Variant P-value
7:117160308:G:T 848 19 0.022 0.1404 0.4742
7:117160319:G:GT 931 439 0.472 0.2003 0.003651
7:117160319:GT:G 1145 225 0.197 -0.2067 0.003311
7:117160319:GTT:G 470 7 0.015 0.216 0.5411
7:117163435:G:GT 100 393 0.254 0.1275 0.31
7:117163435:G:GTT 240 323 0.743 -0.07606 0.395
7:117164446:GA:G 1210 82 0.068 -0.1514 0.1385





Figure 3.5. Recombination ratio and linkage disequilibrium observed in 762 F508del 
homozygous samples (1524 chromosomes) across a 506 kb re-sequencing region 
surrounding CFTR. 
Top– Recombination ratio plotted by genomic location.  A recombination event occurring 
within intron 15 of CFTR indicated by red arrow.  Below is an intronic and exonic map of 
known RefSeq genes, and re-sequencing study variants with MAF > 1% (hg19 
coordinates). Bottom- LD heat map of variants with MAF > 2% in the F508del 




to the heat-map of r
2
 values below.  Within the heatmap, black boxes indicate an r
2
 value 
of 1 or complete LD, while white boxes indicate an r
2
 of 0 or linkage equilibrium.  Three 
proposed LD blocks are outlined (triangles).  The first extends from the start of the 
sequencing capture to intron 3 of WNT2.  LD block 1 then extends from the WNT2 locus 
to intron 15 of CFTR.  And finally, LD block 2 extends from intron 15 of CFTR to the 
end of the sequencing capture (mid-CTTNBP2). LD blocks 0 and 2 likely extend far 












Haplotypes observed in 762 F508del homozygous samples (1524 chromosomes) 
across the CFTR locus. 
Top– Intronic and exonic map of CFTR, and contained re-sequencing study variants with 
MAF > 1%. Bottom  – Representation of CFTR SNP haplotypes with MAF > 1% and 
MHF > 0.5%.  Each numbered variant is represented vertically by blue (reference allele) 
or red (alternate allele) squares.  Each haplotype is represented horizontally as a row, 
with respective minor haplotype frequencies to the left.  Two LD blocks are shown, with 
primary recombination events indicated by bold connecting lines.  LD block 1 shows one 








Linkage disequilibrium across a 506 kb re-sequencing region surrounding CFTR 
after removing samples with alternative ancestral haplotype in LD block 2. 
Top– Intronic and exonic map of known RefSeq genes, and re-sequencing study variants 
with MAF > 1% (hg19 coordinates). Bottom- LD heat map of variants with MAF > 2% 
in F508del chromosomes lacking the intron 15 recombination event.  Dashed red lines 
indicate projection of variants from their genomic positions to the heat-map below.  
Within the heatmap, black boxes indicate an r
2
 value of 1 or complete LD, while white 
boxes indicate an r
2 
of 0 or linkage equilibrium.  The three proposed LD blocks are 
outlined (triangles).  The first extends from the start of the sequencing capture to intron 3 
of WNT2.  LD blocks one and two are now indistinguishable, indicating the alternative 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table3.10. Tagging of CFTR SNPs with MAF > 1%, r
2
 > 0.9. 


















































Figure 3.8. Linkage disequilibrium observed in 762 F508del homozygous samples 
and 163 alternative allele samples (1850 chromosomes total) across a 506kb region 
surrounding CFTR.   
Top– Red arrows indicate approximate locations of RFLPs originally used to map CFTR 
Middle- Intronic and exonic map of known RefSeq genes. Bottom- LD heat map of 
variants with MAF > 5% in the combined population of F508del homozygotes and 
alternative genotype samples.  Within the heatmap, black boxes indicate an r
2
 value of 1 
or complete LD, while white boxes indicate an r
2 
of 0 or linkage equilibrium.  One 
primary recombination event in intron 15 is visualized (blue box), and additional 



















Carbonic Anhydrase XII Deficiency 
In Chapter 2 of this thesis, I described the discovery of disease causing variants 
within CA12 in three patients with hyponatremic dehydration and elevated sweat chloride 
levels.  While this gene had previously been implicated in a similar phenotype in a 
consanguineous population, our study describes three novel loss-of-function variants, two 
of which were inherited in a compound heterozygous fashion in a non-consanguineous 
patient. This research has advanced our understanding of both the CA12 deficiency 
phenotype and the molecular etiology of this disease state.  Finally, it has provided key 
support for the hypothesis that bicarbonate imbalance may play a substantial role in CF 
lung disease. 
The Mild Lung Phenotype in CA12 Deficiency 
A novel finding in Chapter 2 is the observation of lung disease in a patient with 
loss of function mutations in CA12.  We understand there may be unrelated or additional 
causes of lung disease in this singleton, and address these possibilities here.  Patients with 
CA12 deficiency were likely only directed to our study due to their distinct elevated 
sweat chloride levels, which suggest a CF diagnosis.   While one patient reported in 
Chapter 2 had mild bronchiectasis and some lung infections consistent with mild CF, it 
is possible these symptoms would have been overlooked by a primary care physician had 
her sweat test been within a normal range.  Indeed, everyone is susceptible to viral and 
bacterial infections which are generally treated at home and never formally cultured.  
Perhaps this individual would have been given more time to clear infections had she been 




disease in this patient was not observed in any other CA12 deficient patient.  This could 
be for various reasons including:  reduced vigilance for these symptoms in the other 
pedigrees (they were not seen regularly at a CF clinic), a younger age (perhaps lung 
disease manifests itself later), or altered presentation due to different causative mutations 
(allele specific expressivity – to be addressed below).   
One reason for the potential variable expressivity of lung disease in CA12 patients 
may be the inheritance of alternative disease causing variants. A key finding reported in 
Chapter 2 was that both the previously reported mutation and the mutations presented in 
our study led to complete loss of CA XII function.  Previously, it was reported that the 
initial mutation only resulted in a 30% reduction in enzymatic activity (86).  However, 
we believe that this original assay was erroneous in that it failed to consider the salt 
concentrations at the active site of the protein (which is extracellular).  After correcting 
for the salt concentration, both mutations led to loss of function.  This highlights the 
importance of a thorough and thoughtful investigation into the molecular etiology of any 
given candidate disease causing variant.  
We additionally show in our study the correct trafficking and localization of CA 
XII protein resulting from the reported missense mutations in a polarized cell line 
(MDCK).  During revisions and publication of our manuscript, another group reported 
that one of these mutations (E143K), resulted in altered glycosylation of the protein and 
retention in the ER in MDCK cells (187).  While our initial findings suggested possible 
altered glycosylation states of the E134K mutant, this appeared to have no effect on 
protein localization. These discrepant findings could be due to an altered expression of 




vectors expressing these supposedly identical CA12 transcripts may somehow play a role 
here.  An ideal way to resolve this question would be to obtain primary cells from a 
patient harboring this mutation, which may not be possible.  Sharing vectors and 
repeating these assays would be a more feasible and warranted endeavor, such that 
hopefully one finding is replicable. While it is interesting to posit that these two protein 
expressing mutations may have alternative paths to loss of function, the phenotypes in 
these two pedigrees are largely concordant in that both lack mild lung disease trait.  
However, the proband with lung disease happens to carry mutations which result in little 
to no protein expression.  Perhaps the residual protein in the other pedigrees somehow 
staves off lung disease, but this seems highly unlikely as our functional studies have 
shown lack of enzymatic activity in these proteins even when they reach the cell surface.  
I posit that the more likely reason for the variable expressivity of the lung phenotype in 
CA12 deficiency is either a delayed onset or incomplete phenotyping. 
As noted in Chapter 2, the mechanism by which loss of CA XII function results 
in elevated sweat chloride levels remains to be fully elucidated. The recent paper by 
Hong and Muhammad also found that CA XII may activate the chloride/bicarbonate 
exchanger AE2 as part of a larger metabolon in the sweat duct (187).  Additional studies 
will be needed to determine other potential members of this ion modulating complex in 
the sweat duct, and their role in maintenance of sweat chloride concentration.  
Additional CA12 Carrier Cohorts for Future Studies 
Future studies into CA12 deficiency may benefit from recruiting patients with 




patients, it is possible that there are additional CA12 deficient patients which could be 
ascertained through the study of idiopathic bronchiectasis patients.   Our laboratory is 
currently planning to recruit and screen potential CA12 variant carriers from this large 
population (~110,000 patients in the US) (114).  The other key presentations which led to 
ascertainment of CA12 deficient patients were failure to thrive (FTT) and hyponatremic 
dehydration.  For the oldest proband in our study, failure to thrive in infancy led to sweat 
testing and a CF diagnosis.  While sweat testing is indicated in patients with failure to 
thrive, it may not be ordered by all clinicians or practices.  Thus, it is possible that some 
children with FTT may carry disease causing variants within CA12, and these patients 
have not been ascertained to CF clinics or our study.  The other proband presented in 
Chapter 2 was initially sweat tested due to an episode of hyponatremic dehydration.  
There are 1.5 million pediatric outpatient visits per year in the U.S. due to dehydration.  
Of these, approximately 3% can be further classified as hyponatremic dehydration (188).  
Given that sweat testing is not necessarily indicated for dehydration, it is possible that 
additional CA12 deficient patients are present in this population.  Of note, the pedigree 
reported in Chapter 2 lives in an arid climate, where one might expect an increased 
incidence of dehydration in the general population.  Heatwaves and strenuous activity can 
often lead to general dehydration, but some individuals may be more or less susceptible 
to developing these symptoms.  Interestingly, a heat-wave in 1948 led to an increased 
frequency of admission of CF patients to pediatric wards for symptoms of dehydration 
(3).  This increase in admissions was likely due to the increased salt wasting in CF 
coupled with the high surface area to volume ratio of small children (189).   Given that 




there are additional affected individuals who may present with dehydration only during 
certain extremities of weather or exercise.  The latter may be justified by a recent study of 
hyponatremia in triatheletes (190).  Here, the authors showed that ~10% of these athletes 
developed hyponatremia, and another 0.3% developed critical hyponatremia.  There 
athletes may be carriers of CA12 disease causing variation, or may have similar genetic 
alterations in genes of related pathways (including CFTR).   This is yet another source 
where additional insights into the pathways related to salt wasting could be gained.  
A Novel Role for Bicarbonate in CF 
This study has challenged the notion that cystic fibrosis is solely a disease of 
chloride transport. Our work reveals that a CF-like phenotype in both the sweat gland and 
lung can arise from aberrant bicarbonate levels.  The renown CF researcher and patient, 
Dr. Paul Quinton, has hypothesized that altered bicarbonate transport by CFTR may be 
driving pathogenesis in CF (99).  In 2008, he suggested that in the CF lung, excess 
bicarbonate (due to its role as a buffer) sequesters cations required for the proper 
expansion of mucins.  This theory has since been tested and proven correct in both mouse 
and pig animal models of CF (191, 192). Additionally, others have shown that the lung 
ASL pH in both CF patients and other animal models is significantly reduced (193).  This 
change in pH has been linked to an altered host defense and an increase in infections 
(194).  Future studies into the role of bicarbonate in CF pathogenesis will require a 
thorough understanding of bicarbonate regulatory pathways, and how these vary among 
tissues.  The work presented in Chapter 2 has added to and will continue to inform this 




The Atypical Cystic Fibrosis Study 
There are additional patients with elevated sweat chloride levels in the absence of 
CFTR mutations who have been recruited to the atypical CF sequencing study.  Like our 
CA12 samples, some of these probands and families have had whole exome or whole 
genome sequencing analysis in hopes of elucidating causative variation.  Unfortunately, 
these assays have not yielded many candidate genes for the elevated sweat chloride 
phenotype.  Clinical exome sequencing has a diagnostic rate between 10 and 30% (195).  
The variability here arises from many sources including the degree of previous genetic 
analysis, the distinct phenotype, the genetic power (larger pedigrees are more 
informative), and the NGS diagnostic criteria.   
The low yield of candidate genes in the atypical CF study may be a combination 
of three possible sources.  First, a large number of candidate variants and genes do not 
meet the high threshold of genetic and bioinformatic evidence needed to move forward 
into functional studies.   A candidate gene must have two likely loss of function 
mutations that are inherited in a manner consistent with the pedigree’s phenotype, be 
expressed in the tissues of interest (primarily the sweat gland and lung), and play a role in 
relevant pathways (i.g. ion transport, secretion, etc).  Many candidate genes in the 
atypical study meet only two out of these three criteria.  It is possible that mutations in 
multiple genes which may be interacting in a pathway could lead to disease in these 
patients (poly or multi-genic inheritance) (196).  However, the methods to assay this 
disease mechanism are limited and still not well understood (197).  Re-analysis of this 
cohort in a pathway specific manner may yield additional candidates as the tools become 




Like other genome sequencing studies, NGS analysis in the atypical CF study is 
contingent upon a reliable phenotype and distinct inheritance pattern.  We have observed 
multiple families where sweat chloride levels have changed over time in the same patient, 
or a pattern of inheritance within the family is unclear.  Often, individuals may have 
borderline sweat chloride levels and could easily be labelled as either affected or 
unaffected.  Variability in sweat chloride levels is a known phenomenon, but has not been 
well characterized.  Some factors which may influence sweat chloride levels include 
hormone cycles (198), salt intake and hydration, and variability that is inherent with the 
sweat testing method.  There is an ongoing effort to understand this variability in the 
Cutting laboratory, and future publications will hopefully elucidate some of these 
mechanisms.   Additionally, there is currently an active collaboration to develop a 
wearable sweat chloride sensor that would record these intra-individual changes in real 
time.  This additional research will help further refine and increase the overall usability of 
the sweat chloride phenotype.   
Finally, the atypical CF sequencing study may simply not be assaying the 
causative variation in these patients.  Exomes only assay the ~1% of the genome which 
we believe to be functional.  While there is significant evidence this is a good filter when 
looking for disease causing variation, there are still additional types of variation that can 
lead to disease.  These include deep intronic splice variants, copy number variation, and 
modification of regulatory regions.  Additional sources of heritable factors include 
epigenetic factors and mitochondrial DNA.  As the cost of whole genome sequencing 




However, bioinformatics methods to query these datasets are still in active development, 
and it will likely be many years before we can realize their full potential. 
 
Towards Understanding Phenotypic Variability in CF 
Chapter 3 described a targeted resequencing study of the CFTR locus in a 
specific cohort of CF patients.  This work makes several contributions to the 
understanding of genetic modifiers in CF.  We reported novel variation in cis with the 
F508del allele, as well as variation within nearby blocks of linkage disequilibrium.  
These findings challenged the previous notion that the F508del homozygous population 
was highly homogeneous in regards to the CFTR locus.  We also describe a 
recombination event, refined in this study to intron 15 of CFTR, which contributes a 
significant portion of the common variation observed.  This recombination event appears 
to be specific to the F508del population, suggesting it arose after the founder mutation.  
Finally, and perhaps most interestingly, some of the variation in this cohort was found to 
associate with variability in two key CF traits: sweat chloride levels and lung function.  
While other rare revertants have been described (see Chapter 1), this is the first report of 
CFTR variation beyond the F508del mutation modifying either lung function or sweat 
chloride levels in a large cohort.   
   Nearly all bioinformatics assays of NGS biomedical research data are hypothesis 
generating work, and this study is no exception.  The rare and common variation 
identified in these studies will be further assayed for mechanisms by which they may 




cis with F508del could be assayed in vitro for revertant potential.  We have already 
shared some of these variants with collaborators working on CFTR transcriptional rate 
studies, in order to determine whether the alternative codon usage could ultimately lead 
to protein misfolding.  Next, many additional studies will be needed to further dissect the 
associations observed during region based burden testing.  In many cases, the primary 
hypothesis to be resolved at these loci will be whether the rare and common variation 
could alter CTCF binding or overall chromatin structure.  There has been extensive work 
defining the CFTR topologically associated domain in recent years by three key groups 
(148, 156, 168).  It is my hope that this study has now provided these groups with an 
additional toolset with which to assay mechanisms regulating expression of the CFTR 
protein.  As mentioned in Chapter 3, the findings presented should be tested for 
replication in a larger cohort.  Often, studying small to moderate sized cohorts can lead to 
a higher frequency of false positive findings through population stratification and other 
methods.  Many means of replication exist, which could include genotyping common 
variants under a given burden test peak, or alternatively genotyping all variation under 
each peak through a similar targeted sequencing method.  Ideally, these assays would be 
conducted in a novel cohort, potentially recruited at alternative sites.   
While this work now introduces the idea of genetic modifiers within and near the 
CFTR locus, there have been ongoing efforts to elucidate genome-wide variation 
associated with CF lung function through GWAS (see Chapter 1).  Beyond the scope of 
this thesis, there were additional previously identified modifier loci for both lung disease 
and CF related diabetes sequenced in the cohort presented in Chapter 3.  Each locus will 




present under these large GWAS peaks.  However, many of these loci were only typed in 
phase 2 of the study, so the cohort size is quite small.  Future work in the Cutting lab in 
collaboration with other sites includes whole genome sequencing of a large CF patient 
cohort (~5000).  This study will allow for not only replication of the study in presented in 
Chapter 3, but will allow for a genome-wide assay of rare variation which may 
contribute to the phenotypic heterogeneity in this population.  By recognizing the 
mechanisms which lead to mild disease in select patients, these studies may inform future 
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Loss of function mutations in Carbonic Anhydrase XII result in hyponatremic dehydration and 
elevated sweat chloride concentration.   
 
2010    American Chemistry Society National Meeting 
Evolution of single-stranded DNA molecular recognition elements via CE-SELEX: Detection of TNT 
and biosensor applications 
 
Grant Award:  Complete Genomics Whole Genome Sequencing Initiative 
VAAST: A novel variant annotation and prioritization tool for determining the causative alleles of 











Previous Research Experiences 
2009    Summer Intern:  University of Pennsylvania and CHoP Gene Therapy Program 
-The role of VAMP-3 in lamellar body formation, trafficking, and fusion pathways during fetal lun 
development.  
2008    Summer Intern:  University of Pittsburgh School of Medicine Department of 
Neuropharmacology 
-The role of select phosphatases in cell signaling pathways crucial to mitochondrial motility in    
primary cortical neurons. 
2008-10   Undergraduate Research:  West Virginia University Eberly College – Sooter  Lab 
-Molecular Recognition Elements (MREs) generated via in vitro selection or SELEX of an ssDNA 




 American Chemistry Society (2006-2010)  
 American Society of Human Genetics (2012-Current) 
 
Teaching Experience____________________________________________________________ 
2007-2010 Tutoring Chemistry, Biology, and Mathematics – West Virginia University 
2008-2010  Peer Led Team Learning – West Virginia University 
2009-2010 General Chemistry II Teaching Assistant – West Virginia University 
2010-2014 Private Tutoring High School Math and Sciences 
 
